



# 2021 PAN PACIFIC LYMPHOMA CONFERENCE

August 9-13 / Fairmont Orchid / Big Island, Hawaii

## CONFERENCE PROGRAM



University of Nebraska  
Medical Center

Nebraska Medicine

Connect with us on  and  using #PPLC21 #IamUNMC

# Download the event app



Stay up-to-date on PPLC 2021 by downloading the **FREE** event app!

1. Search for the “**eventScribe**” app in the Apple App Store or in Google Play or scan the QR code below.
2. Search for “**2021 PPLC**” inside the eventScribe App.
3. Login to create an account and use “**Hawaii21**” as the event code.



**Laptop and other mobile device users, go to**  
<https://tinyurl.com/unmc2021>

*We gratefully acknowledge the following for support of this conference:*

#### **PLATINUM SUPPORTER**

Incyte Corporation

#### **GOLD SUPPORTERS**

AstraZeneca Pharmaceuticals  
BeiGene  
Pharmacyclics LLC, an AbbVie Company,  
and Janssen Biotech Inc., administered by  
Janssen Scientific Affairs LLC

#### **SILVER SUPPORTERS**

Genentech, a member of the Roche Group  
MorphoSys US Inc.  
Seagen, Inc.  
Takeda Pharmaceuticals USA Inc.

#### **BRONZE SUPPORTERS**

ADC Therapeutics America, Inc.  
GlaxoSmithKline  
Sanofi Genzyme

#### **COPPER SUPPORTERS**

AbbVie Inc.  
Acrotech Biopharma LLC  
Adaptive Biotechnologies  
Bristol-Myers Squibb  
Epizyme, Inc.  
Gamida Cell Inc.  
Genmab  
Karyopharm Therapeutics Inc.  
Kite Pharma, Inc.  
Novartis  
Oncopeptides  
TG Therapeutics Inc.

#### **SUPPORTER**

Verastem Oncology

#### **EDUCATIONAL GRANTS**

AbbVie Inc.  
ADC Therapeutics America, Inc.  
AstraZeneca Pharmaceuticals  
Bristol-Myers Squibb  
Daiichi Sankyo, Inc.  
Incyte Corporation  
Gilead Sciences, Inc.  
Kite Pharma, Inc.  
Seattle Genetics Inc.



# WELCOME

## Welcome to the 2021 Pan Pacific Lymphoma Conference!

Since its inception in 1994, PPLC has grown and become a premier international conference on the latest advances in lymphoma. This year, we have decided to host a hybrid conference with an in-person activity at the Fairmont Orchid, Hawaii and a virtual option for attendees who are not able to travel. We are very happy to welcome over 550 attendees!

For your easy reference and convenience, we encourage you to download the conference mobile app or visit [tinyurl.com/unmc2021](https://tinyurl.com/unmc2021). Please note that all references to conference days and times follow Hawaii Standard Time (HST).

Here's what you can expect for the week:

- **Day 1 (Monday):** We will feature an Interprofessional Education Day, with various presentations for the interprofessional lymphoma team members.
- **Days 2-5 (Tuesday through Friday):** Expert faculty will present in scientific sessions covering What's Next in Lymphoma, Moving CAR-T Forward, Ongoing Debates in Lymphoma, Best Management Strategies. Loretta J. Nastoupil, MD will present the James O. Armitage Lymphoma Clinical Investigator Award Lecture and Ranjana H. Advani, MD will deliver the Oliver Press Memorial Lecture, "Historical Development of Hodgkin Therapy at Stanford," in memory of our esteemed colleague, Oliver W. Press, MD, PhD.
- **Days 2-4 (Tuesday through Thursday) afternoons:** Join us for the Ask the Experts sessions where we will discuss iNHL, HGBCL, cHL, PTCL and MM. Also, on Day 2/Tuesday, we will have our fast-paced Lymphoma Jeopardy with four teams competing for Day 3/Wednesday's Pineapple Cup Lymphoma Jeopardy Finals.
- **Days 1-5 (Monday through Friday):** If you are joining us in-person, please come visit the exhibits in the Plaza Ballroom.
- **Days 1-4 (Monday through Thursday):** Please make time to join the industry-supported satellite symposiums. If you haven't registered to attend these, you may do so online. Note that AMA and ANCC credits are available for these symposiums held in conjunction with PPLC21.
- **Days 1-5 (Monday through Friday):** The conference e-poster gallery detailing the latest research in lymphoma and transplantation are also available via the conference mobile app and online.
- **Day 2 (Tuesday) evening:** If you are attending in-person, please join us for the Welcome Reception from 7-9 pm at the Croquet Lawn where you can meet and network with other conference attendees. Light hors d'oeuvres and beverages will be served. Paid/registered guests are welcome to attend.
- **Day 4 (Thursday) evening:** In-person attendees are encouraged to join the Conference Dinner from 7-9 pm at the Turtle Pointe. Dinner and beverages will be served while we enjoy a live band performance. Paid/registered guests are welcome to attend.

Friendly reminders if you are attending in-person:

- Please be sure that you and your paid guests wear your conference badge at all times.
- The attire for this conference is casual; layered clothing is recommended as temperature in meeting rooms can fluctuate. A light jacket or sweater for outdoor evening activities is suggested. Leave your ties in your room!

If you are on Twitter or Instagram, we encourage you to tag your photos and posts **#PPLC21** and **#lamUNMC**.

Once again, thank you for joining the 2021 Pan Pacific Lymphoma Conference. **Aloha!**

## Conference Directors



**James O. Armitage, MD**  
Joe Shapiro Professor of Medicine  
Division of Oncology and Hematology  
Department of Internal Medicine  
University of Nebraska Medical Center



**Matthew A. Lunning, DO, FACP**  
Associate Professor  
Division of Oncology and Hematology  
Department of Internal Medicine  
University of Nebraska Medical Center



**Robbe L. Peetz, MBA, PA-C**  
Advanced Practice Provider Manager  
Cancer Services  
Nebraska Medicine



**Tawny J. Roeder, RN, BSN, BMTCN**  
Case Manager  
Blood and Marrow Transplantation  
Division of Oncology and Hematology  
Department of Internal Medicine  
Nebraska Medicine



**Julie M. Vose, MD, MBA**  
Neumann M. and Mildred E. Harris Professor  
Chief, Division of Oncology and Hematology  
Department of Internal Medicine  
University of Nebraska Medical Center

# CONFERENCE INFORMATION

## *Conference Registration Information*

The Conference Registration and Information Desk is located in the Grande Ballroom Foyer on the Lobby Level of the Fairmont Orchid, Hawaii. Attendees may pick up their conference materials and name badges at this location. The Registration/Information Desk is open during the following times:

Sunday, August 8	2:00 p.m. - 4:00 p.m.
Monday, August 9	7:00 a.m. - 4:00 p.m.
Tuesday, August 10	7:00 a.m. - 12:00 p.m.
Wednesday, August 11	7:00 a.m. - 12:00 p.m.
Thursday, August 12	7:00 a.m. - 12:00 p.m.
Friday, August 13	7:00 a.m. - 12:00 p.m.

## *Mobile Device Use*

We encourage you to use your mobile device to download the 2021 PPLC event app so you can have access to the entire conference program. Please remember to turn your mobile device to silent or vibrate mode when attending sessions.

## *Poster and Exhibit Hours*

Monday, August 9	7:00 a.m. - 12:00 p.m.
Tuesday, August 10	7:00 a.m. - 12:00 p.m.
Wednesday, August 11	7:00 a.m. - 12:00 p.m.
Thursday, August 12	7:00 a.m. - 12:00 p.m.
Friday, August 13	7:00 a.m. - 10:00 a.m.

## *Internet Access*



Complimentary WiFi is available in the conference area.  
Network: UNMCPPLC21  
Password: PPLC2021

Complimentary in-room WiFi is available for guests of the Fairmont Orchid, Hawaii.

## *Photography and Audio Visual Recording Policy*

Please be aware that during the 2021 Pan Pacific Lymphoma Conference, attendees, vendors, guests, and exhibitors may be photographed or videotaped by UNMC and/or third parties authorized by UNMC. Some of these photographs or videos may be displayed by UNMC in future publications or other materials. By virtue of your attendance, you agree to allow UNMC to use photographs of you in these promotional materials.

Photographs taken for the purpose of sharing on social media are allowed, but should avoid showing presentation slides. Please use #PPLC21 when posting on social media.

## *Children and Other Accompanying Guests*


PPLC 2021 does not offer childcare services. Due to limited seating capacity and the highly technical nature of the program, children are not allowed to attend sessions. For their safety, children must be accompanied by an adult at all times during the conference.

Registered accompanying guests may join conference registrants at the following food functions:

- Continental breakfasts (7-9 a.m.) and breaks as part of the main conference from Monday through Friday
- Welcome Reception on Tuesday evening
- Conference Dinner on Thursday evening


Name badges will be required at these conference food functions.

# Venue Floor Plan



## Session and Room Assignments

- F GRANDE BALLROOM FOYER**  
 Conference Registration
- G GRANDE BALLROOM**  
 Scientific Sessions                      Ask the Experts  
 Lymphoma Jeopardy                      Satellite Symposiums
- P PLAZA BALLROOM**  
 Continental Breakfast                      Refreshment Breaks  
 Exhibits
- CROQUET LAWN**  
 Welcome Reception — Tuesday, August 10 from 7-9 p.m.
- TURTLE POINTE**  
 Conference Dinner — Thursday, August 12 from 7-9 p.m.



# EDUCATION INFORMATION

## *Target Audience*

The 2021 Pan Pacific Lymphoma Conference is one of the largest gatherings of clinicians and researchers specializing in the areas of lymphoma and transplantation. The 2021 conference will benefit members of the multidisciplinary lymphoma clinical team including oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists.

## *Conference Objectives*

At the conclusion of the conference, the participant should be better able to:

1. Discuss patient and disease-related factors that impact the diagnosis, prognosis, and approaches to treatment of hematologic malignancies, including lymphoma, myeloma, leukemia
2. Assess clinical trial data of current and emerging agents and regimens that impact management strategies for patients with Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)
3. Describe currently available and novel investigational strategies for the treatment and maintenance of patients with multiple myeloma (MM)
4. Evaluate results of clinical trials investigating treatment approaches for patients with acute and chronic leukemias
5. Develop strategies to integrate emerging therapeutic strategies into the armamentarium for patients with hematologic malignancies
6. Identify factors that improve patient quality-of-life including appropriate patient counseling and mitigating treatment-related adverse events
7. Analyze factors that impact enrollment of patients with lymphoma, leukemia and myeloma into clinical trials examining novel treatment approaches
8. Explain the roles of the interprofessional health care team in the diagnosis, treatment, management and support of lymphoma and hematologic malignancies

## *Disclosure Declaration*

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:

## **FACULTY**

### **Jeremy S. Abramson, MD, MMSc**

CONSULTANT: AbbVie; Allogene; AstraZeneca; BeiGene; Bluebird Bio; C4 Therapeutics; Celgene; EMD Serono; Genentech; Incyte; Karyopharm; Kite Pharma; Kymera; MorphoSys

### **Ranjana H. Advani, MD**

CONSULTANT: ADC Therapeutics; BeiGene; Daiichi Sankyo; Incyte Corp.; Karyopharm; Kura; Portola Pharmaceuticals; Sanofi  
RESEARCH FUNDING: Bristol Myers Squibb; Celgene; Kura; Merck; Roche/Genentech; Seattle Genetics; Takeda/Millennium  
ADVISORY BOARD: Roche/Genentech  
HONORARIUM: Roche/Genentech

### **Stephen M. Ansell, MD, PhD**

GRANT/RESEARCH SUPPORT: ADC Therapeutics; Bristol Myers Squibb; Regeneron; Seattle Genetics; Trillium  
RESEARCH FUNDING: Bristol Myers Squibb; Regeneron; Seattle Genetics; Trillium

### **James O. Armitage, MD**

CONSULTANT: Ascentage; Samus Therapeutics  
MEMBER, BOARD OF DIRECTORS: Cardiff Oncology

### **Muhamed Baljevic, MD, FACP**

ADVISORY BOARD: Bristol Myers Squibb; Janssen Biotech; Oncopeptides  
CONSULTANT: Bristol Myers Squibb  
IRC MEMBER FOR PHASE 3 BOSTON: Karyopharm

### **Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD**

DEPARTMENTAL RESEARCH FUNDING: Amgen Inc.; Bristol Myers Squibb; Pfizer  
SPEAKERS BUREAU: Takeda/Millennium

### **Nancy L. Bartlett, MD**

ADVISORY BOARD: ADC Therapeutics; Genentech/Roche; Seattle Genetics, Inc.  
GRANT/RESEARCH SUPPORT: ADC Therapeutics; Celgene; Genentech/Roche; Janssen; Merck; Millennium; Pharmacyclics  
RESEARCH FUNDING: ADC Therapeutics; Autolus; Bristol Myers Squibb; Celgene; Forty Seven, Inc.; Genentech/Roche; Janssen; Kite Pharma; Merck; Millennium; Pharmacyclics; Seattle Genetics, Inc.

### **R. Gregory Bociek, MD, MSc, FRCP(C)**

CONSULTANT: Innate Pharma  
DATA SAFETY MONITORING BOARD: Innate Pharma

### **Reiner J. Brentjens, MD, PhD**

ROYALTIES: Bristol Myers Squibb  
CONSULTANT: Bristol Myers Squibb  
SPEAKER: Bristol Myers Squibb  
ADVISOR: Gracell Therapeutics

### **Carla Casulo, MD**

RESEARCH FUNDS: Bristol Myers Squibb; Genentech; Gilead Sciences, Inc.; Verastem

### **Bruce D. Cheson, MD, FACP, FAAAS, FASCO**

CONSULTANT: BeiGene; Karyopharm; Merck Sharp & Dohme Corp.

### **Jonathon B. Cohen, MD, MS**

ADVISOR: Adaptive Biotechnologies; Adicet; AstraZeneca; BeiGene; Janssen; Kite/Gilead; Loxo Oncology  
ADVISORY BOARD: Adicet; AstraZeneca; BeiGene;  
CONSULTANT: Janssen  
RESEARCH FUNDING: Adicet; AstraZeneca; Bristol Myers Squibb/Celgene; Genentech; LAM; Loxo Oncology; Takeda  
GRANT/RESEARCH SUPPORT: Bristol Myers Squibb/Celgene; Genentech; LAM; Loxo Oncology; Takeda

### **Alexey V. Danilov, MD, PhD**

CONSULTANT: AbbVie; AstraZeneca; Bayer Healthcare Pharmaceuticals; BeiGene; Bristol-Meyers Squibb; Genentech; Janssen/Pharmacyclics; TG Therapeutics  
RESEARCH FUNDING: AbbVie; AstraZeneca; Bayer Healthcare Pharmaceuticals; Bristol-Meyers Squibb; Epizyme; Genentech; SecuraBio; Takeda/Millennium; TG Therapeutics

### **Matthew S. Davids, MD, MMSc**

CONSULTANT: AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene  
RESEARCH SUPPORT: AbbVie; Ascentage Pharma; AstraZeneca  
ADVISORY BOARD: Ascentage Pharma; AstraZeneca  
GRANT/RESEARCH SUPPORT: Ascentage Pharma; AstraZeneca

# EDUCATION INFORMATION

## **Timothy S. Fenske, MD, MS**

CONSULTANT: AbbVie; Adaptive Biotechnologies; Genentech; Karyopharm; Kite Pharma; MorphoSys; Pharmacyclics; Sanofi Genzyme; TG Therapeutics; Verastem

SPEAKER: Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; Bristol Myers Squibb; Genentech; Karyopharm; Kite Pharma; Sanofi Genzyme; Seattle Genetics; TG Therapeutics; Verastem

## **Richard I. Fisher, MD**

CONSULTANT: Bayer

## **Christopher R. Flowers, MD, MS, FASCO**

CONSULTANT: AbbVie; Bayer; BeiGene; Celgene Corporation; Denovo Biopharma; Genentech/Roche; Genmab A/S; Gilead Sciences, Inc.; Janssen/Pharmacyclics; Karyopharm; Pharmacyclics; Spectrum

RESEARCH FUNDING: AbbVie; Acerta; Adaptimmune; Allogene; Amgen Inc.; Bayer Healthcare Pharmaceuticals; Burroughs Wellcome Fund; Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research; Celgene; Collectis; Eastern Cooperative Oncology Group; EMD Serono; Genentech/ Roche; Gilead Sciences, Inc.; Guardant; Iovance; Janssen; Kite Pharma; MorphoSys; National Cancer Institute; Nektar; Novartis Pharmaceuticals; Pfizer; Pharmacyclics; Sanofi; Takeda/Millennium; TG Therapeutics; V Foundation; Xencar; Ziopharm

## **Jonathan W. Friedberg, MD, MMSc**

DATA SAFETY MONITORING BOARD: Astellas

## **Tara M. Graff, DO, MS**

SPEAKER - ADVISORY BOARD: AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene; Karyopharm; TG Therapeutics

## **Krishna Gundabolu, MBBS, FACP**

ADVISORY BOARD: Biomarín; Blueprint Medicines; Bristol Myers Squibb; Jazz Pharmaceuticals; Novartis Pharmaceuticals; Pfizer

STOCKHOLDER: Geron

CLINICAL TRIAL PI: Samus Therapeutics

## **Keely M. Hack, MD**

CONSULTANT: Denovo Biopharma; Genentech/Roche; Genmab A/S; Gilead Sciences, Inc.; Janssen/Pharmacyclics; Karyopharm; Pharmacyclics; Spectrum

RESEARCH FUNDING: Collectis; Eastern Cooperative Oncology Group; EMD Serono; Genentech/Roche; Gilead Sciences, Inc.; Guardant; Iovance; Janssen; Kite Pharma; MorphoSys; National Cancer Institute; Nektar; Novartis Pharmaceuticals; Pfizer; Pharmacyclics; Sanofi; Takeda/Millennium; TG Therapeutics; V Foundation; Xencar; Ziopharm

## **Steven M. Horwitz, MD**

CONSULTANT: Acrotech Biopharma; ADC Therapeutics; Astex; C4 Therapeutics; Celgene; Janssen Biotech; Kura Oncology; Kyowa Hakko Kirin Pharma; Myeloid Therapeutics; ONO Pharmaceuticals; Seattle Genetics; SecuraBio; Takeda/Millennium; Trillium Therapeutics; Verastem; Vividion Therapeutics

RESEARCH GRANT SUPPORT: ADC Therapeutics; Affimed; Aileron Therapeutics; Celgene; Daiichi Sankyo; Forty Seven, Inc.; Kyowa Hakko Kirin Pharma; SecuraBio; Takeda/Millennium; Trillium Therapeutics; Verastem

## **Brad S. Kahl, MD**

CONSULTANT: AbbVie; ADC Therapeutics; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb; Celgene; Genentech; Incyte; Janssen; Karyopharm; Kite; Pharmacyclics; Roche; Teva

## **John P. Leonard, MD**

ADVISORY BOARD: Miltenyi Biotec

CONSULTANT: AbbVie; Bayer; Bristol Myers Squibb; Celgene; Genentech; Genmab A/S; Gilead; Incyte; Juno Therapeutics; Karyopharm; Miltenyi Biotec; Regeneron; Sutro

## **Matthew A. Lunning, DO, FACP<sup>®</sup>**

CONSULTANT: Acrotech Biopharma; AstraZeneca/Acerta; Beigene; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen/Pharmacyclics; Karyopharm; Kite; Legend Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Spectrum; TG Therapeutics; Verastem

RESEARCH GRANT SUPPORT: Bristol-Myers Squibb; Curis

ADVISORY BOARD: Celgene

## **David G. Maloney, MD, PhD**

ADVISORY BOARD: A2 Biotherapeutics; Amgen; Bristol Myers Squibb; Celgene Corporation; Genentech; Janssen; Juno Therapeutics; Kite Pharma; MorphoSys; Novartis; Pharmacyclics

STOCK OPTIONS: A2 Biotherapeutics

RESEARCH FUNDING: Celgene Corporation; Juno Therapeutics; Kite Pharma

PATENTS PENDING: Juno Therapeutics

## **David B. Miklos, MD, PhD**

RESEARCHER: Adaptive Biotechnologies; Adicet; Allogene; Kite/Gilead; Miltenyi Biotec; Novartis

## **Alison J. Moskowitz, MD**

RESEARCH SUPPORT: ADC Therapeutics; Bristol Myers Squibb; Incyte Corp.; Merck; Seattle Genetics

CONSULTANT: Imbrium Therapeutics L.P.; Janpix Ltd.; Merck miRagen; Seattle Genetics; Takeda/Millennium

**Loretta J. Nastoupil, MD**

HONORARIUM: ADC Therapeutics; Bayer; Celgene; Epizyme; Gilead; Janssen; Novartis; TG Therapeutics

ADVISORY BOARD: ADC Therapeutics; Bayer; Celgene; Epizyme; Gilead; Janssen; Novartis; TG Therapeutics

**Grzegorz S. Nowakowski, MD**

CONSULTANT: Bantam

**Susan M. O'Brien, MD**

RESEARCH SUPPORT: Acerta

CONSULTANT: Amgen

ADVISORY COMMITTEE/BOARD MEMBER: AstraZeneca

**Tawny J. Roeder, RN, BSN, BMTCN<sup>®</sup>**

SPEAKERS BUREAU: Gilead

**Kerry J. Savage, MD, MSc, FRCP**

CONSULTANT: Bristol Myers Squibb; Merck

HONORARIUM: Bristol Myers Squibb; Merck; Seattle Genetics

INSTITUTIONAL RESEARCH FUNDING: Roche/Genentech

ADVISORY BOARD: Seattle Genetics

**Nina Shah, MD**

RESEARCH FUNDING: Celgene; Janssen; Bluebird Bio; Sutro Biopharma; Teneobio

ADVISORY ROLE: Genentech; Surface Oncology; Precision Biosciences; GSK; Nektar; Amgen; Indapta Therapeutics; Sanofi; Bristol Myers Squibb

STOCK: Indapta Therapeutics

**Sonali M. Smith, MD**

GRANT/RESEARCH SUPPORT: Acerta; Celgene; Epizyme; Novartis; Pharmacyclics; Roche/Genentech; TG Therapeutics

ADVISORY BOARD: Bantam; Bristol Myers Squibb; Celgene; Janssen; Karyopharm; MorphoSys; Pharmacyclics

CONSULTANT: Bantam; Bristol Myers Squibb; Celgene; Janssen; MorphoSys

CLINICAL TRIALS: Acerta; Epizyme; Karyopharm; Pharmacyclics; Roche/Genentech; TG Therapeutics

**Judith Trotman, MBChB, FRACP, FRCPA**

CLINICAL TRIALS: Beigene; Celgene Corporation; Janssen/Pharmacyclics; Roche/Genentech

**Julie M. Vose, MD, MBA<sup>®</sup>**

ADVISORY COMMITTEE/BOARD MEMBER/ADVISORY BOARD: AbbVie; Acerta/AstraZeneca; Pharmacyclics

CONSULTANT: MorphoSys

**Luhua (Michael) Wang, MD**

GRANT/RESEARCH SUPPORT: AstraZeneca; Janssen

CONSULTANT: AstraZeneca

**Jason R. Westin, MD, MS, FACP**

CONSULTANT: ADC Therapeutics; AstraZeneca; Bristol Myers Squibb; Genentech; Gilead Sciences; Iksuda; MorphoSys; Novartis; Umoja

CLINICAL RESEARCH FUNDING: AstraZeneca; Bristol Myers Squibb; Genentech; Gilead Sciences; MorphoSys; Novartis

**Andrew D. Zelenetz, MD, PhD**

CONSULTANT: AbbVie; Adaptive Biotechnology; Amgen; AstraZeneca; Celgene; Gilead; Janssen; Mei Pharma; MorphoSys; Novartis; Roche/Genentech

DMC CHAIR: BeiGene; Bristol Myers Squibb; Celgene; Juno

RESEARCH: Beigene; Gilead; Mei Pharma; Roche

**Pier Luigi Zinzani, MD, PhD**

HONORARIA/SPEAKER'S BUREAU: Astellas; Celltrion; Gilead; MSD

ADVISOR: Gilead; Kirin Kyowa; Verastem

**OFF-LABEL, EXPERIMENTAL OR INVESTIGATIONAL USE OF DRUGS DISCLOSURE****R. Gregory Bociek, MD, MSc, FRCP(C)**

Clinical trials | Manufacturer: various | Off-label Use: Cytotoxics, monoclonal antibodies, targeted therapies

**Bruce D. Cheson, MD, FACP, FAAAS, FASCO**

Epcoritamab | Manufacturer: Genmab | Off-label Use: Lymphoma

Glofitamab | Manufacturer: Genentech | Off-label Use: Lymphoma

Magrolimab | Manufacturer: Gilead | Off-label Use: Lymphoma

Mosunetuzumab | Manufacturer: Roche-Genentech | Off-label Use: Lymphoma

Odrenextamab | Manufacturer: Regeneron | Off-label Use: Lymphoma

**Matthew S. Davids, MD, MMSc**

Venetoclax | Off-label Use: Management of NHL

**Timothy S. Fenske, MD, MS**

Breyanzi | Manufacturer: Bristol Myers Squibb | Off-label Use: Mantle cell lymphoma

Venetoclax | Manufacturer: AbbVie | Off-label Use: Mantle cell lymphoma

**Christopher R. Flowers, MD, MS, FASCO**

Bi-specific antibodies | Off-label Use: Experimental

**Jonathan W. Friedberg, MD, MMSc**

Novel agents for lymphoma | Off-label Use: unapproved

# EDUCATION INFORMATION

**Keely M. Hack, MD**

Bi-specific antibodies | Off-label Use: Experimental

**Steven M. Horwitz, MD**

Checkpoint inhibitors for MF + SS

**John P. Leonard, MD**

Investigational Lymphoma Therapy | Manufacturer: Multiple | Off-label Use: Off-label Lymphoma Therapy

**David G. Maloney, MD, PhD**

CAR-T Cells | Manufacturer: Juno; Kite; Celgene

**Alison J. Moskowitz, MD**

Nivolumab | Manufacturer: Bristol Myers Squibb | Off-label Use: front-line use for Hodgkin lymphoma

Pembrolizumab | Manufacturer: Merck | Off-label Use: front-line use for Hodgkin lymphoma

**Nina Shah, MD**

CAR T cells | Manufacturer: Bristol Myers Squibb, Janssen | Off-label Use: myeloma

**Sonali M. Smith, MD**

I will be discussing the use of unlabeled/unapproved drugs or devices.

**Luhua (Michael) Wang, MD**

LOXO-305 | Manufacturer: Loxo | Off-label Use: Data

**Jason R. Westin, MD, MS, FACP**

Axi-cel | Manufacturer: Gilead | Off-label Use: 1L DLBCL

Ibrutinib | Manufacturer: Janssen | Off-label Use: 1L DLBCL

Lenalidomide | Manufacturer: Bristol Myers Squibb | Off-label Use: 1L DLBCL

Polatuzumab | Manufacturer: Genentech | Off-label Use: 1L DLBCL

Tafasitamab | Manufacturer: MorphoSys | Off-label Use: 1L DLBCL

**Andrew D. Zelenetz, MD, PhD**

ClonoSeq | Manufacturer: Adaptive Biotech | Off-label Use: offers reliable way to assess how disease burden changes

**Pier Luigi Zinzani, MD, PhD**

Bortezomib | Manufacturer: J&J | Off-label Use: off label

Copanlisib | Manufacturer: Bayer | Off-label Use: Investigational use

Duvelisib | Manufacturer: Verastem | Off-label Use: Investigational use

Idelalisib | Manufacturer: Gilead | Off-label Use: Investigational use

Lanalidomide | Manufacturer: Bristol Myers Squibb | Off-label Use: off label

Parsaclisib | Manufacturer: Incyte | Off-label Use: Investigational use

Umbralisib | Manufacturer: TG Therapeutics | Off-label Use: Investigational use

Zanubrutinib | Manufacturer: Beigene | Off-label Use: Investigational use

The following faculty members have nothing to disclose:

**Catalina Amador, MD**

**Christopher D'Angelo, MD**

**Charles A. Enke, MD**

**Theresa Franco, MSN, RN**

**David S. Kroll, MD**

**Peihua (Peggy) Lu, MD**

**Jared E. Matya, PharmD, BCOP**

**Craig H. Moskowitz, MD**

**Robbe L. Peetz, MBA, PA-C**

**Christin A. Tiegs Heiden, MD**

**Meg Trehwitt, APN-BC, AOCNP**

**PLANNING COMMITTEE**

**James O. Armitage, MD** 

**Matthew A. Lunning, DO, FACP** 

**Tawny J. Roeder, RN, BSN, BMTCN** 

**Julie M. Vose, MD, MBA** 

The following planning committee members have nothing to disclose:

**Jared E. Matya, PharmD, BCOP**

**Renee Paulin, MSN, RN, CWOCN**

**Robbe L. Peetz, MBA, PA-C**

**Brenda Ram, CMP, CHCP**

## Continuing Education Credits



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the

American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### PHYSICIANS

The University of Nebraska Medical Center designates this live activity for a maximum of 29.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSES

The University of Nebraska Medical Center designates this activity for up to 29.25 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

### PHARMACISTS



The University of Nebraska Medical Center designates this activity for 29.25 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 30 days after the activity completion.

## Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 29.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

## How to Claim Credit

### PHYSICIANS CLAIMING MOC CREDIT:

To obtain credit, you must complete the evaluation in the app.

- On the front screen, select the Evaluation tile
- Update your profile information
- Complete the pretest for MOC credit
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation
- Complete the post test for MOC credit
- Retrieve your certificate

### NON-PHYSICIANS OR PHYSICIANS NOT CLAIMING MOC CREDIT:

To obtain credit, you must complete the evaluation in the app.

- On the front screen, select the Evaluation tile
- Update your profile information
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation
- Retrieve your certificate

**The deadline to claim continuing education credit for this conference is October 13, 2021.**

### CLAIMING PHARMACY CREDIT:

In order for pharmacists to claim credit for their participation in the conference, each individual must complete the evaluation in the conference app, and ensure that their date of birth (mm/dd), as well as their NABP ID # is on record with UNMC/CCE. Your NABP ID# is different than your license number.

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation. UNMC CCE will supply the necessary information to CPE Monitor.

**We will not be able to accept requests for ACPE credit after September 13, 2021.**

# CONFERENCE AGENDA

## Monday, August 9

### Interprofessional Education

**7:00 a.m.** Conference Registration  / Breakfast 

**7:45 a.m.** Welcome   
Matthew A. Lunning, DO, FACP and Tawny J. Roeder, RN, BSN, BMTCN

### SCIENTIFIC SESSIONS

**8:00 a.m.** High Cost Services in Lymphoma  
Theresa Franco, MSN, RN

**8:40 a.m.** Involving Palliative Care in Lymphoma Management  
Meg Trehwhitt, APN-BC, AOCNP

**9:10 a.m.** Recognizing and Treating Depression and Anxiety in Lymphoma Patients  
David S. Kroll, MD

**9:40 a.m.** Supportive Therapies for Novel Oral Therapies  
Jared E. Matya, PharmD, BCOP

**10:10 a.m.** Break 

**10:25 a.m.** Radiographic Images in Lymphoma  
Christin A. Tiegs Heiden, MD

**11:05 a.m.** Anticoagulation Management in Hematologic Malignancies  
Krishna Gundabolu, MBBS, FACP

**11:35 a.m.** Utilization of Advanced Practice Providers in Lymphoma: Roundtable  
Robbe L. Peetz, MBA, PA-C

**12:15 p.m.** Adjourn

### SATELLITE SYMPOSIUMS

**1:00-2:30 p.m.** Expert Second Opinion - Investigators Discuss How They and Their Colleagues Navigate Emerging Clinical Research and Challenging Cases of Acute Myeloid Leukemia and Myelodysplastic Syndromes  
*Administered by Research To Practice*  
Supported by Educational Grants from AbbVie, Inc. and Bristol-Myers Squibb Company and Takeda Oncology

 All times are displayed in Hawaii Standard Time (HST)

**3:00-5:00 p.m.** Expert Tumor Board to Address Challenging Cases of Relapsed/Refractory Aggressive and Indolent Lymphomas

*Administered by Bio Ascend*

Supported by Educational Grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, Morphosys and TG Therapeutics, Inc.

**5:00 p.m.** Adjourn

## Tuesday, August 10

**7:00 a.m.** Conference Registration  / Breakfast 

**7:30 a.m.** Welcome   
James O. Armitage, MD and Julie M. Vose, MD, MBA

### SCIENTIFIC SESSIONS

#### What's Next in Lymphoma

MODERATOR: Julie M. Vose, MD, MBA

**7:40 a.m.**  What's Next for PET/CT in Lymphoid Malignancies  
Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD

**8:05 a.m.** What's Next for Pathologic Assessment in Lymphoid Malignancies  
Catalina Amador, MD

**8:30 a.m.** What's Next for Radiotherapy in Lymphoid Malignancies  
Charles A. Enke, MD

**8:55 a.m.**  What's Next for Antibody Drug Conjugates (ADCs) in Lymphoid Malignancies  
Brad S. Kahl, MD

**9:20 a.m.**  What's Next for Bispecific T-cell Engager (BiTE) Antibodies in Lymphoid Malignancies  
Christopher R. Flowers, MD, MS, FASCO

**9:45 a.m.**  What's Next for Non-CD20 Based Monoclonal Antibodies in Lymphoid Malignancies  
Nancy L. Bartlett, MD

**10:10 a.m.** Break 

MODERATOR: Richard I. Fisher, MD

**10:30 a.m.** BEACOPP: Past, Present and Incorporating Brentuximab Vedotin and Checkpoint Inhibitors in Hodgkin Lymphoma  
James O. Armitage, MD

**10:55 a.m.**  ABVD: Past, Present and Incorporating Brentuximab Vedotin and Checkpoint Inhibitors in Hodgkin Lymphoma  
Alison J. Moskowitz, MD

**11:20 a.m.**  PET Pearls and PET-Falls – the Role of PET in Follicular Lymphoma  
Judith Trotman, MBChB, FRACP, FRCPA

**11:45 a.m.** Novel Imaging Modalities in Multiple Myeloma  
Christin A. Tiegs Heiden, MD

**12:10 p.m.** Novel Combination Therapies in Newly Diagnosed Multiple Myeloma  
Nina Shah, MD

**12:35 p.m.** Novel Strategies in Relapsed and Refractory Multiple Myeloma  
Muhamed Baljevic, MD, FACP

**1:00 p.m.** Adjourn

## SATELLITE SYMPOSIUM

**1:00-3:00 p.m.** Beyond the Guidelines - Investigator Perspectives on the Management of Chronic Lymphocytic Leukemia  
*Administered by Research To Practice*  
Supported by Educational Grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd., Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC and TG Therapeutics, Inc..

## LYMPHOMA JEOPARDY

### Semi-Finals

MODERATOR: Matthew A. Lunning, DO, FACP

**3:00-4:00 p.m.** Semi's #1  
TEAM NORTH: Stephen M. Ansell, MD, PhD; Timothy S. Fenske, MD, MS; and Sonali M. Smith, MD  
TEAM EAST: Jeremy S. Abramson, MD, MMSc; Matthew S. Davids, MD, MMSc; and Andrew D. Zelenetz, MD, PhD

Semi's #2  
TEAM SOUTH: Jonathon B. Cohen, MD, MS; Christopher D'Angelo, MD; and Loretta J. Nastoupil, MD  
TEAM WEST: Ranjana H. Advani, MD; Alexey V. Danilov, MD, PhD; and David B. Miklos, MD, PhD

## ASK THE EXPERTS

**4:00-5:00 p.m.** iNHL  
MODERATOR: Matthew A. Lunning, DO, FACP  
Jonathon B. Cohen, MD, MS; Matthew S. Davids, MD, MMSc; and Loretta J. Nastoupil, MD

## SATELLITE SYMPOSIUM

**5:00-6:30 p.m.** Best Practices for Using Novel Therapies for R/R DLBCL  
*Administered by Medscape Oncology*  
Supported by Educational Grants from Karyopharm Therapeutics and Morphosys US Inc.

## WELCOME RECEPTION

Croquet Lawn

**7:00-9:00 p.m.**  
Conference participants and registered accompanying guests are invited to join the reception. Name badges required.

# Wednesday, August 11

**7:00 a.m.** Breakfast 

## SCIENTIFIC SESSIONS

### Moving CAR-T Forward

MODERATOR: Matthew A. Lunning, DO, FACP

**7:30 a.m.**  Management of CAR-T Toxicities  
David G. Maloney, MD, PhD

**7:55 a.m.** Manipulating the T-cell Before and After Apheresis  
Jeremy S. Abramson, MD, MMSc

**8:20 a.m.**  Manipulating the CAR-T Construct  
Renier J. Brentjens, MD, PhD

**8:45 a.m.** Is There a Best T-cell Phenotype for CAR-T?  
David B. Miklos, MD, PhD

**9:10 a.m.**  CAR-T in China  
Peihua (Peggy) Lu, MD

**9:35 a.m.** CAR-T for Other NHL  
Julie M. Vose, MD, MBA

**10:00 a.m.** Break 

# CONFERENCE AGENDA

 All times are displayed in Hawaii Standard Time (HST)

## Thursday, August 12

MODERATOR: Julie M. Vose, MD, MBA	
<b>10:15 a.m.</b>	<b>James O. Armitage Lymphoma Clinical Investigator Award</b> Loretta J. Nastoupil, MD
<b>11:05 a.m.</b>	<b>Oliver Press Memorial Lecture</b> Historical Development of Hodgkin Therapy at Stanford Ranjana H. Advani, MD
<b>LYMPHOMA JEOPARDY</b> 	
<b>11:55 a.m.</b>	<b>Finals</b> Matthew A. Lunning, DO, FACP
<b>12:45 p.m.</b>	<b>Adjourn</b>
<b>SATELLITE SYMPOSIUM</b> 	
<b>1:00-3:00 p.m.</b>	<b>Current and Emerging CAR T-Cells and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies</b> <i>Administered by Bio Ascend</i> Supported by Educational Grants from Bristol-Myers Squibb Company and Legend Biotech
<b>ASK THE EXPERTS</b> 	
<b>3:00-4:00 p.m.</b>	<b>HGBCL</b> MODERATOR: James O. Armitage, MD Jeremy S. Abramson, MD, MMSc and Andrew D. Zelenetz, MD, PhD
<b>4:00-5:00 p.m.</b>	<b>cHL</b> MODERATOR: R. Gregory Bociek, MD, MSc, FRCP(C) Ranjana H. Advani, MD and Craig H. Moskowitz, MD
<b>SATELLITE SYMPOSIUM</b> 	
<b>5:00-6:00 p.m.</b>	 <b>A Team-Based Approach to Optimizing Outcomes for Patients with CLL</b> <i>Administered by Medscape Oncology</i> Supported by Educational Grants from AbbVie, Inc. and TG Therapeutics, Inc.
<b>6:00 p.m.</b>	<b>Adjourn</b>

<b>7:00 a.m.</b>	<b>Breakfast</b>	
<b>SCIENTIFIC SESSIONS</b>		
<b>Ongoing Debates in Lymphoma</b> MODERATOR: Matthew A. Lunning, DO, FACP/ Tara M. Graff, DO, MS		
<b>7:30 a.m.</b>	<b>Utilization of a BTK Inhibitor in 1st Line CLL/SLL</b> Alexey V. Danilov, MD, PhD and Susan M. O'Brien, MD	
<b>8:00 a.m.</b>	<b>Integration of Non-CAR-T Based Immunotherapies in the Management of Non-Hodgkin Lymphoma</b> Stephen M. Ansell, MD, PhD and Bruce D. Cheson, MD, FACP, FAAAS, FASCO	
<b>8:30 a.m.</b>	<b>Utilization of a Cell Free DNA Assessment in Non-Hodgkin Lymphoma Management</b> Jeremy S. Abramson, MD, MMSc and Andrew D. Zelenetz, MD, PhD	
<b>9:00 a.m.</b>	 <b>Management of High Risk Follicular Lymphoma</b> Carla Casulo, MD	
<b>9:30 a.m.</b>	 <b>Utilization of Oral Therapies in First Line Indolent Non-Hodgkin Lymphoma Management</b> Jonathan W. Friedberg, MD, MMSc	
<b>10:00 a.m.</b>	<b>Break</b>	
MODERATORS: Keely M. Hack, MD/James O. Armitage, MD		
<b>10:15 a.m.</b>	<b>Utilization of Central Nervous System Prophylaxis in High Grade B-cell Lymphomas</b> Sonali M. Smith, MD	
<b>10:45 a.m.</b>	 <b>Utilization of X Plus R-CHOP in High Grade B-cell Lymphomas</b> Jason R. Westin, MD, MS, FACP	
<b>11:15 a.m.</b>	 <b>Utilization of Radiotherapy in Hodgkin Lymphoma</b> Alison J. Moskowitz, MD	
<b>11:45 a.m.</b>	 <b>Utilization of Routine Imaging During Continuous Oral Therapies</b> John P. Leonard, MD	
<b>12:15 p.m.</b>	<b>Utilization of Maintenance Rituximab in Mantle Cell Lymphoma</b> Timothy S. Fenske, MD, MS	
<b>12:45 p.m.</b>	<b>Adjourn</b>	

## SATELLITE SYMPOSIUM G

**1:00-3:00 p.m.** Cases from the Community - Investigators Discuss Emerging Research and Actual Patients with Multiple Myeloma

*Administered by Research To Practice*  
Supported by Educational Grants from AbbVie Inc., Bristol-Myers Squibb Company, Oncopeptides, and Takeda Oncology

## ASK THE EXPERTS G

**3:00-4:00 p.m.** PTCL  
MODERATOR: Julie M. Vose, MD, MBA  
Stephen M. Ansell, MD, PhD and Matthew A. Lunning, DO, FACP

**4:00-5:00 p.m.** MM  
MODERATOR: Matthew A. Lunning, DO, FACP  
Muhamed Baljevic, MD, FACP and Nina Shah, MD

## CONFERENCE DINNER Turtle Pointe

**7:00-9:00 p.m.**  
Conference participants and registered accompanying guests are invited to join. Name badges required.

# Friday, August 13

**7:00 a.m.** Breakfast P

## SCIENTIFIC SESSIONS G

### Best Management Strategies

MODERATOR: Matthew A. Lunning, DO, FACP

**7:30 a.m.** Best Management of Relapsed or Refractory Follicular Lymphoma  
Jonathon B. Cohen, MD, MS

**7:55 a.m.** Best Management of Relapsed or Refractory Marginal Zone Lymphoma  
Pier Luigi Zinzani, MD, PhD

**8:20 a.m.** Best Management of Relapsed or Refractory HGBCL Post CAR-T Cell Therapy  
Grzegorz S. Nowakowski, MD

**8:45 a.m.** Best Management of TP53 Mutated Mantle Cell Lymphoma  
Luhua (Michael) Wang, MD

**9:10 a.m.**  Best Management of CD30+ PTCL Post Exposure to Brentuximab Vedotin  
Kerry J. Savage, MD, MSc, FRCPC

**9:35 a.m.** Best Management of Hodgkin Lymphoma Post Exposure to Brentuximab Vedotin and Checkpoint Inhibitor  
Craig H. Moskowitz, MD

**10:00 a.m.** Break P

**10:15 a.m.** Best Management of Relapsed and Refractory CLL/SLL Post BTK and BCL-2 Exposure  
Alexey V. Danilov, MD, PhD

**10:40 a.m.**  Best Management of Advanced Stage Mycosis Fungoides and Sezary Syndrome  
Steven M. Horwitz, MD

**11:05 a.m.** Best Management of Cutaneous B-cell Lymphoma  
R. Gregory Bociek, MD, MSc, FRCPC(C)

**11:30 a.m.** Best Management of HIV Associated High Grade B-cell Lymphomas  
Jeremy S. Abramson, MD, MMSc

**11:55 a.m.** Take Home Messages from 2021 Pan Pacific Lymphoma Conference  
Matthew A. Lunning, DO, FACP

**12:20 p.m.** Adjourn

# CONFERENCE FACULTY

## Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, MA

## Ranjana H. Advani, MD

Saul A. Rosenberg Professor of Lymphoma, Department of Medicine/Oncology, Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA

## Catalina Amador, MD

Associate Professor; Section Medical Director, Bone Marrow Laboratory, Hematopathology Laboratory, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE

## Stephen M. Ansell, MD, PhD

Chair, Mayo Clinic Lymphoma Group; Professor of Medicine, Mayo Clinic, Rochester, MN

## James O. Armitage, MD★

Joe Shapiro Professor of Medicine, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## Muhamed Baljevic, MD, FACP

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD

Professor of PET Imaging and NIHR Research Professor, KCL and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom

## Nancy L. Bartlett, MD

Professor of Medicine, Koman Chair in Medical Oncology, Washington University School of Medicine, St. Louis, MO

## R. Gregory Bociek, MD, MSc, FRCP(C)

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## Renier J. Brentjens, MD, PhD

Director, Cellular Therapeutics; Associate Chair, Junior Faculty Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

## Carla Casulo, MD

Associate Professor, James P. Wilmot Cancer Center, Department of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

## Bruce D. Cheson, MD, FACP, FAAAS, FASCO

Scientific Advisor to the Lymphoma Research Foundation and with Johns Hopkins Medicine, Bethesda, MD

## Jonathon B. Cohen, MD, MS

Associate Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

## Christopher D'Angelo, MD

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## Alexey V. Danilov, MD, PhD

Professor, Department of Hematology & Hematopoietic Cell Transplantation; Associate Director, Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

## Matthew S. Davids, MD, MMSc

Associate Professor of Medicine, Harvard Medical School; Director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute, Boston, MA

## Charles A. Enke, MD

Professor and Chair, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE

## Timothy S. Fenske, MD, MS

Professor, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

## Richard I. Fisher, MD

President and CEO, The Robert C. Young MD Chair in Cancer Research, Fox Chase Cancer Center, Philadelphia, PA

## Christopher R. Flowers, MD, MS, FASCO

Professor and Chair, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

## Theresa Franco, MSN, RN

Vice President, Cancer Center Clinical Operations & Radiology, Fred & Pamela Buffett Cancer Center, Nebraska Medicine, Omaha, NE

## Jonathan W. Friedberg, MD, MMSc

Director, James P. Wilmot Cancer Institute; Samuel Durand Professor of Medicine, University of Rochester Medical Center, Rochester, NY

## Tara M. Graff, DO, MS

Medical Oncology and Hematology Associates of Iowa, Des Moines, IA

## Krishna Gundabolu, MBBS, FACP

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

## Keely M. Hack, MD

General Hematologist and Medical Oncologist, Sanford Cancer Center, Sioux Falls, SD

## Steven M. Horwitz, MD

Associate Attending, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

## Brad S. Kahl, MD

Professor of Medicine; Director, Lymphoma Program, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

## David S. Kroll, MD

Associate Vice Chair for Program Development and Innovation, Department of Psychiatry, Brigham Health, Boston, MA

## John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology; Associate Dean for Clinical Research, Executive Vice Chairman, Weill Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY

**Peihua (Peggy) Lu, MD**

Medical Executive President of Lu Daopei Hospital; Director of Lymphoma and Multiple Myeloma Center; Director of Hematology and Oncology Department; Lu Daopei Hospital, Beijing, China

**Matthew A. Lunning, DO, FACP★**

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**David G. Maloney, MD, PhD**

Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor of Medicine, Division of Oncology, University of Washington, Seattle, WA

**Jared E. Matya, PharmD, BCOP**

Focused Population Pharmacist, Blood and Marrow Transplant, Nebraska Medicine, Omaha, NE

**David B. Miklos, MD, PhD**

Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA

**Alison J. Moskowitz, MD**

Medical Oncologist; Clinical Director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, New York, NY

**Craig H. Moskowitz, MD**

Physician in Chief, Cancer Service Line, Sylvester Comprehensive Cancer Center; Professor of Medicine, Miller School of Medicine, University of Miami Health System, Miami, FL

**Loretta J. Nastoupil, MD**

Lead, Early Phase Drug Development, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

**Grzegorz S. Nowakowski, MD**

Associate Professor, Department of Hematology and Oncology, Mayo Clinic, Rochester, MN

**Susan M. O'Brien, MD**

Professor of Medicine; Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials and Research, University of California/Irvine, Orange, CA

**Robbe L. Peetz, MBA, PA-C★**

Advanced Practice Provider, Manager Cancer Services, Nebraska Medicine, Omaha, NE

**Tawny J. Roeder, RN, BSN, BMTCN★**

Case Manager, Blood and Marrow Transplantation, Division of Oncology and Hematology, Department of Internal Medicine, Nebraska Medicine, Omaha, NE

**Kerry J. Savage, MD, MSc, FRCPC**

Professor of Medicine, University of British Columbia; Medical Oncologist, BC Cancer, Vancouver, British Columbia, Canada

**Nina Shah, MD**

Associate Professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

**Sonali M. Smith, MD**

Elwood V. Jensen Professor of Medicine; Interim Chief, Section of Hematology/ Oncology; Director, Lymphoma Program, The University of Chicago, Chicago, IL

**Christin A. Tiegs Heiden, MD**

Assistant Professor, Department of Radiology, Mayo Clinic, Rochester, MN

**Meg Trehwhitt, APN-BC, AOCNP**

Hematology-Oncology Nurse Practitioner, Nebraska Medicine, Omaha, NE

**Judith Trotman, MBChB, FRACP, FRCPA**

Clinical Professor, University of Sydney; Head of Department, Haematology, Concord Repatriation General Hospital, Concord, Australia

**Julie M. Vose, MD, MBA★**

Neumann M. and Mildred E. Harris Professor and Chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Luhua (Michael) Wang, MD**

Professor, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

**Jason R. Westin, MD, MS, FACP**

Associate Professor; Section Chief, Aggressive Lymphoma; Director, Lymphoma Clinical Research Program, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

**Andrew D. Zelenetz, MD, PhD**

Medical Director, Quality Informatics; Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill Cornell Medicine, New York, NY

**Pier Luigi Zinzani, MD, PhD**

Professor of Hematology, Institute of Hematology and Medical Oncology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy

# E-POSTERS

## **Pirtobrutinib (LOXO-305), A Next Generation Highly Selective Non-Covalent BTK Inhibitor in Previously Treated MCL and Other NHL: Phase 1/2 Bruin Study Results**

Alvaro J. Alencar<sup>1</sup>, Nirav N. Shah<sup>2</sup>, James N. Gerson<sup>3</sup>, Manish R. Patel<sup>4</sup>, Bita Fakhri<sup>5</sup>, Wojciech Jurczak<sup>6</sup>, Xuan N. Tan<sup>7</sup>, Katharine L. Lewis<sup>7</sup>, Timothy S. Fenske<sup>2</sup>, Catherine C. Coombs<sup>8</sup>, Ian W. Flinn<sup>9</sup>, David J. Lewis<sup>10</sup>, Steven Le Gouill<sup>11</sup>, M. Lia Palomba<sup>12</sup>, Jennifer A. Woyach<sup>13</sup>, John M. Page<sup>14</sup>, Nicole Lamanna<sup>15</sup>, Jonathon B. Cohen<sup>16</sup>, Minal A. Barve<sup>17</sup>, Paolo Ghia<sup>18</sup>, Toby A. Eyre<sup>19</sup>, Ming Yin<sup>20</sup>, Binoj Nair<sup>20</sup>, Donald E. Tsai<sup>20</sup>, Nora C. Ku<sup>20</sup>, Anthony R. Mato<sup>12</sup>, Chan Y. Cheah<sup>7</sup>, Michael L. Wang<sup>21</sup>, <sup>1</sup>Sylvester Comprehensive Cancer Center, Miami, USA; <sup>2</sup>Medical College of Wisconsin, Milwaukee, USA; <sup>3</sup>University of Pennsylvania, Philadelphia, USA; <sup>4</sup>Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, USA; <sup>5</sup>University of California San Francisco, San Francisco, USA; <sup>6</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland; <sup>7</sup>Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; <sup>8</sup>University of North Carolina at Chapel Hill, Chapel Hill, USA; <sup>9</sup>Sarah Cannon Research Institute, Nashville, USA; <sup>10</sup>University Hospitals Plymouth NHS, Plymouth UK; <sup>11</sup>Service d'hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France; <sup>12</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>13</sup>The Ohio State University Comprehensive Cancer Center, Columbus, USA; <sup>14</sup>Swedish Cancer Institute, Seattle, USA; <sup>15</sup>Herbert Irving Comprehensive Cancer Center, Columbia University, New York, USA; <sup>16</sup>Winship Cancer Institute, Emory University, Atlanta, GA, USA; <sup>17</sup>Mary Crowley Cancer Research, Dallas, USA; <sup>18</sup>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; <sup>19</sup>Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK; <sup>20</sup>Loxo Oncology, Inc, a wholly owned subsidiary of Eli Lilly and Co., Stamford, USA; <sup>21</sup>MD Anderson Cancer Center, Houston, USA

## **Lymphoma Diagnosis Directly from Hematoxylin and Eosin Histopathology Slides**

Areej Alsaafin<sup>1</sup>, Morteza Babaie<sup>1</sup>, Zhe Wang<sup>1</sup>, Mahjabin Sajadi<sup>1</sup>, Soma Sikdar<sup>2</sup>, Adrian Batten<sup>2</sup>, H.R. Tizhoosh<sup>1</sup>, <sup>1</sup>Kimia Lab, University of Waterloo, Waterloo, Ontario, Canada; <sup>2</sup>Department of Pathology, Grand River Hospital, Kitchener, Ontario, Canada

## **Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 4-Year Follow-Up Analysis of the Randomized CLL14 Study**

Othman Al-Sawaf<sup>1,2</sup>, Can Zhang<sup>1</sup>, Sandra Robrecht<sup>1</sup>, Maneesh Tandon<sup>3</sup>, Anesh Panchal<sup>3</sup>, Anna-Maria Fink<sup>1</sup>, Eugen Tausch<sup>4</sup>, Matthias Ritgen<sup>5</sup>, Karl-Anton Kreuzer<sup>1</sup>, Su Young Kim<sup>6</sup>, Clemens-Martin Wendtner<sup>7</sup>, Barbara Eichhorst<sup>1</sup>, Stephan Stilgenbauer<sup>4</sup>, Yanwen Jiang<sup>8</sup>, Michael Hallek<sup>1</sup>, Kirsten Fischer<sup>1</sup>, <sup>1</sup>Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, 50937 Cologne, Germany, +4922147888220, othman.al-sawaf@uk-koeln.de; <sup>2</sup>The Francis Crick Institute, London, United Kingdom; <sup>3</sup>Roche Products Ltd, Welwyn Garden City, United Kingdom; <sup>4</sup>Department of Internal Medicine III, Ulm University, Ulm, Germany; <sup>5</sup>Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany; <sup>6</sup>AbbVie Inc, Chicago, Illinois, United States; <sup>7</sup>Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany; <sup>8</sup>Genentech, San Francisco, California, USA

## **PAK4 and NAMPT as Novel Therapeutic Targets in Diffused Large B-cell Lymphoma, Follicular Small Cleaved Lymphoma and Mantle Cell Lymphoma**

Mahmoud Chaker<sup>1</sup>, Amro Aboukameel<sup>1</sup>, Irfana Muqbil<sup>1</sup>, Mariam Iqbal<sup>1</sup>, William Senapedis<sup>2</sup>, Erkan Baloglu<sup>2</sup>, Erlene Seymour<sup>1</sup>, Radhakrishnan Ramchandren<sup>1</sup>, Jeffrey Zonder<sup>1</sup> and Asfar S. Azmi<sup>1</sup>, <sup>1</sup>Department of Oncology, Wayne State University; <sup>2</sup>Karyopharm Therapeutics Inc, Newton Massachusetts

## **Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial In Progress)**

Nancy L. Bartlett<sup>1</sup>, Christopher A. Yasen<sup>2</sup>, Khaleel Ashraf<sup>3</sup>, William Harwin<sup>4</sup>, Robert Sims<sup>5</sup>, Grzegorz Nowakowski<sup>6</sup>, <sup>1</sup>Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA; <sup>2</sup>Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA; <sup>3</sup>Hematology and Oncology Associates of Alabama, Birmingham, AL, USA; <sup>4</sup>Sarah Cannon Research Institute, Fort Meyers, FL, USA; <sup>5</sup>Seagen Inc., Bothell, WA, USA; <sup>6</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA

## **Barriers to Enrollment in Clinical Trials for Aggressive B-Cell Lymphoma Progressing after CAR T-Cell Therapy**

Evandro Dantas Bezerra<sup>1</sup>, Matthew J. Maurer<sup>2</sup>, Arushi Khurana<sup>1</sup>, Yucai Wang<sup>1</sup>, Matthew Hathcock<sup>1</sup>, Radhika Bansal<sup>1</sup>, Jonas Paludo<sup>1</sup>, Jose Caetano Villasboas<sup>1</sup>, Patrick B. Johnston<sup>1</sup>, N. Nora Bennani<sup>1</sup>, Stephen M. Ansell<sup>1</sup>, Thomas Matthew Habermann<sup>1</sup>, Thomas E. Witzig<sup>1</sup>, Grzegorz S. Nowakowski<sup>1</sup>, Yi Lin<sup>1</sup>; <sup>1</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA; <sup>2</sup>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

## **Early PET Imaging Following CAR-T for Aggressive Lymphoma: Analysis of Metabolic Characteristics and Prognostic Differentiation of Patients Who Do Not Achieve Complete Response at Month 1**

William Breen, Matthew Hathcock, Jason Young, Roman Kowalchuk, Radhika Bansal, Arushi Khurana, N. Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Yucai Wang, Stephen Ansell, Jennifer Peterson, Patrick Johnston, Scott Lester, and Yi Lin. Mayo Clinic, Rochester, Minnesota

## **ENCORE — Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching**

Tyrel Phillips<sup>1</sup>, Kristina S. Yu<sup>2</sup>, Nicholas Liu<sup>2</sup>, Andy Surinach<sup>3</sup>, Carlos Flores<sup>3</sup>, Julie Lisano<sup>2</sup>, Michelle A. Fanale<sup>2</sup>, John M. Burke<sup>4</sup>, <sup>1</sup>University of Michigan Medical School Department of Internal Medicine, Division of Hematology/Oncology, Ann Arbor, MI, USA; <sup>2</sup>Seagen, Bothell, WA, USA; <sup>3</sup>Genesis Research, Hoboken, NJ, USA; <sup>4</sup>Rocky Mountain Cancer Centers, Aurora, CO, USA

### **Reducing the Burden of Oncological Therapy in Children, Adolescents and Young Adults (CAYA) with Mature B-Cell (MBL) and Hodgkin Lymphoma (HL): A Path Forward for Adult Lymphoma**

Mitchell S. Cairo, MD,<sup>1,2,3,4,5</sup> Jessica Hochberg, MD,<sup>1</sup> Qiuhu Shi, PhD,<sup>6</sup> Matthew Barth, MD,<sup>8</sup> Jaclyn Basso, RN, MSN, PNP,<sup>1</sup> Allyson Flower, MD,<sup>1</sup> Humayan Islam, MD,<sup>3</sup> Perry Gerard, MD,<sup>7</sup> Liana Klejmont, PharmD,<sup>1</sup> Aliza Gardenswartz, MD,<sup>1</sup> Lauren Harrison, RN, MSN,<sup>1</sup> Erin Morris, RN,<sup>1</sup> Rodney Miles, MD, PhD,<sup>9</sup> and Stanton Goldman, MD<sup>10</sup>, Departments of Pediatrics<sup>1</sup>, Medicine<sup>2</sup>, Pathology<sup>3</sup>, Microbiology & Immunology<sup>4</sup>, Cell Biology & Anatomy<sup>5</sup>, Biostatistics<sup>6</sup>, and Radiology<sup>7</sup>, New York Medical College, Valhalla, NY, USA; Department of Pediatrics<sup>8</sup>, Roswell Park Cancer Institute, Buffalo, NY, USA; Department of Pathology<sup>9</sup>, University of Utah, Salt Lake City, UT, USA; Department of Pediatrics<sup>10</sup>, Medical City Dallas, Dallas, TX, USA

### **Optimizing Patient Outcomes with Consolidative Radiotherapy in the Salvage Management of Hodgkin Lymphoma**

Brendan Coutu, MD<sup>1</sup>, Elliot Lawrence, MD<sup>1</sup>, Robert G. Bociek, MD<sup>2</sup>, James Armitage, MD<sup>2</sup>, and Charles Enke, MD<sup>1</sup>, <sup>1</sup>Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE; <sup>2</sup>Division of Hematology/Oncology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE

### **Targeting Transcriptional Regulation of Pi3k Signaling Pathway in B-Cell Lymphoma**

Sinisa Dovat<sup>1</sup>, Chandrika Gowda<sup>1</sup>, Yali Ding<sup>1</sup>, and Dhimant Desai<sup>1</sup>, <sup>1</sup>Pennsylvania State University College of Medicine, Hershey, PA, USA

### **An Unclassifiable B-Cell Lymphoma in a Tongue Mass of an 86-Year-Old Female**

Kaia Erickson, MD and Douglas Lynch, MD, University of South Dakota Sanford Medical Center, Sioux Falls, SD, USA

### **ENCORE — Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching**

John M. Burke<sup>1</sup>, Nicholas Liu<sup>2</sup>, Kristina S. Yu<sup>2</sup>, Michelle A. Fanale<sup>2</sup>, Andy Surinach<sup>3</sup>, Carlos Flores<sup>3</sup>, Julie Lisano<sup>2</sup>, Tycel Phillips<sup>4</sup>, 1. Rocky Mountain Cancer Centers, Aurora, CO, USA; 2. Seagen, Bothell, WA, USA; 3. Genesis Research, Hoboken, NJ, USA; 4. University of Michigan Medical School Department of Internal Medicine, Division of Hematology/Oncology, Ann Arbor, MI, USA

### **Healthcare Resource Utilization and Costs in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Using Real-World Data from the United States**

Christina Cool, MPH [1], Chaoling Feng, PhD [2], Sally W. Wade, MPH [3], Reina Rau, MPH [1] Kenneth Ching, PhD [1], Liliosa Nyamutswa, MPH [2], Behzad Kharabi, MD [2] Adam Duvall MD, MPH [4], [1] PRECISIONheor, New York, NY USA [2] Kite, A Gilead Company, Santa Monica, CA USA [3] Wade Outcomes Research and Consulting, Salt Lake City, UT USA [4] University of Chicago, Chicago, IL, USA

### **Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial In Progress)**

Ian Flinn<sup>1</sup>, Judah D. Friedman<sup>2</sup>, Linda Ho<sup>3</sup>, Hun Ju Lee<sup>4</sup>, <sup>1</sup>Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; <sup>2</sup>University Hospitals Seidman Cancer Center, Cleveland, OH, USA; <sup>3</sup>Seagen Inc., Bothell, WA, USA; <sup>4</sup>MD Anderson Cancer Center, Houston, TX, USA

### **Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary Syndrome**

Francine Foss, MD<sup>1</sup>; Takahiro Ito, MSc<sup>2</sup>; Karen Dwyer, BA<sup>2</sup>; Fiona Herr, PhD<sup>3</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, USA; <sup>2</sup>Kyowa Kirin, Inc., Princeton, NJ, USA; <sup>3</sup>Kyowa Kirin, Inc., Bedminster, NJ, USA

### **Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase IB/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) In Patients (PTS) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)**

Elizabeth Budde,<sup>1</sup> Nilanjan Ghosh,<sup>2</sup> Julio Chavez,<sup>3</sup> Izidore S. Lossos,<sup>4</sup> Amitkumar Mehta,<sup>5</sup> Kathleen Dorritie,<sup>6</sup> Manali Kamdar,<sup>7</sup> Raluca Negricea,<sup>8</sup> Song Pham,<sup>9</sup> Maria Hristopoulos,<sup>9</sup> Ling-Yuh Huw,<sup>9</sup> Carol O'Hear,<sup>9</sup> Yasuhiro Oki,<sup>9</sup> Iris To,<sup>9</sup> Catherine Diefenbach<sup>10</sup>, <sup>1</sup>City of Hope National Medical Center, Duarte, CA, USA; <sup>2</sup>Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA; <sup>3</sup>Moffitt Cancer Center, Tampa, FL, USA; <sup>4</sup>Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA; <sup>5</sup>O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL, USA; <sup>6</sup>UPMC Hillman Cancer Center, Pittsburgh, PA, USA; <sup>7</sup>University of Colorado Cancer Center, Aurora, CO, USA; <sup>8</sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland; <sup>9</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>10</sup>Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA

### **Hypomagnesemia at Time of Autologous Stem Cell Transplantation is Associated with an Increased Risk of Failure in Patients with Diffuse Large B-Cell Lymphoma**

Jennifer J. Gile<sup>1</sup> M.D., Camden L. Lopez<sup>2</sup> M.S., Gordon J. Ruan<sup>1</sup> M.D., Matthew A. Hathcock<sup>2</sup>, Jithma P. Abeykoon<sup>1</sup> M.D., Joy R. Heimgartner<sup>3</sup> RDN, Nikola A. Baumann Ph.D., M. Molly McMahon<sup>3</sup> M.D., Ivana N. Micallef<sup>1</sup> M.D., Patrick B. Johnston<sup>1</sup> M.D., Ph.D., Jose C. Villasboas Bisneto<sup>1</sup> M.D., Luis F. Porrata<sup>1</sup> M.D., Jonas Paludo<sup>1</sup> M.D., Stephen M. Ansell<sup>1</sup> M.D., Ph.D., William J. Hogan<sup>1</sup> M.B., B.Ch., Thomas E. Witzig<sup>1</sup> M.D., <sup>1</sup>Division of Hematology, Department of Medicine, and <sup>2</sup>Department of Biomedical Statistics and Informatics and <sup>3</sup>Division of Endocrinology, Department of Medicine, Mayo Clinic Rochester, MN 55905

### **Overview of 3rd Line Therapies for Follicular Lymphoma in the Modern Era: An Advanced Practice Provider Perspective**

Guerrero, M.D. and Mistry, H.E., The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

# E-POSTERS

## 5-Year Update of the Murano Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Following Fixed-Duration Venetoclax-Rituximab Therapy

Rosemary Harrup,\*<sup>1</sup> Arnon P. Kater,\*<sup>2</sup> Thomas J. Kipps,<sup>3</sup> James D'Rozario,<sup>4</sup> Carolyn Owen,<sup>5</sup> Tadeusz Robak,<sup>6</sup> Javier de la Serna,<sup>7</sup> Marco Montillo,<sup>8</sup> Clemens Mellink,<sup>2</sup> Mariana Cota Stirner,<sup>9</sup> Jenny Wu,<sup>10</sup> Yanwen Jiang,<sup>10</sup> Maria Thadani-Mulero,<sup>11</sup> Marcus Lefebure,<sup>11</sup> Michelle Boyer,<sup>11</sup> John F. Seymour<sup>12</sup>, <sup>1</sup>Royal Hobart Hospital, University of Tasmania, Tasmania, Australia; <sup>2</sup>Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; <sup>3</sup>UCSD Moores Cancer Center, San Diego, CA, USA; <sup>4</sup>The John Curtin School of Medical Research, Australian National University, Canberra, Australia; <sup>5</sup>University of Calgary, Calgary, Canada; <sup>6</sup>Medical University of Lodz, Lodz, Poland; <sup>7</sup>Hospital Universitario 12 de Octubre, Madrid, Spain; <sup>8</sup>Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; <sup>9</sup>AbbVie, North Chicago, IL, USA; <sup>10</sup>Genentech, Inc. South San Francisco, CA, USA; <sup>11</sup>Roche Products Ltd, Welwyn Garden City, UK; <sup>12</sup>Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia  
\*Co-first authors listed alphabetically

## The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin (BV) and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients (PTS) with CD30-Positive Peripheral T-CELL Lymphoma (PTCL)

Steven Horwitz<sup>1</sup>, Owen A. O'Connor<sup>2</sup>, Barbara Pro<sup>3</sup>, Tim Illidge<sup>4</sup>, Swaminathan Iyer<sup>5</sup>, Ranjana Advani<sup>6</sup>, Nancy L. Bartlett<sup>7</sup>, Jacob Haaber Christensen<sup>8</sup>, Franck Morschhauser<sup>9</sup>, Eva Domingo-Domenech<sup>10</sup>, Giuseppe Rossi<sup>11</sup>, Won Seog Kim<sup>12</sup>, Tatyana Feldman<sup>13</sup>, Tobias Menne<sup>14</sup>, David Belada<sup>15</sup>, Árpád Illés<sup>16</sup>, Kensei Tobinai<sup>17</sup>, Kunihiro Tsukasaki<sup>18</sup>, Su-Peng Yeh<sup>19</sup>, Andrei Shustov<sup>20</sup>, Andreas Hüttmann<sup>21</sup>, Kerry J. Savage<sup>22</sup>, Sam Yuen<sup>23</sup>, Pier Luigi Zinzani<sup>24</sup>, Harry Miao<sup>25</sup>, Veronica Bunn<sup>25</sup>, Keenan Fenton<sup>26</sup>, Michelle Fanale<sup>26</sup>, Markus Puhlmann<sup>26</sup>, Lorenz Trümper<sup>27</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>E. Couric Cancer Center, University of Virginia, Charlottesville, VA, USA and TG Therapeutics, New York, NY, USA; <sup>3</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, USA; <sup>4</sup>Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust, Manchester, UK; <sup>5</sup>MD Anderson Cancer Center/University of Texas, Houston, TX, USA; <sup>6</sup>Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford, CA, USA; <sup>7</sup>Washington University School of Medicine, St. Louis, MI, USA; <sup>8</sup>Odense University Hospital, Odense, Denmark; <sup>9</sup>CHRU de Lille, Lille cedex, Nord-Pas-de-Calais, France; <sup>10</sup>Institut Catala D'oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; <sup>11</sup>Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy; <sup>12</sup>Samsung Medical Center, Seoul, Republic of Korea; <sup>13</sup>Hackensack University Medical Center, Hackensack, NJ, USA; <sup>14</sup>Freeman Hospital, Newcastle upon Tyne, England; <sup>15</sup>4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové, Czech Republic and Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic; <sup>16</sup>Debreceni Egyetem, Debrecen, Hajdu-Bihar, Hungary; <sup>17</sup>National Cancer Center Hospital, Tokyo, Japan; <sup>18</sup>Saitama Medical University International Medical Center, Saitama, Japan; <sup>19</sup>China Medical University Hospital, Taichung, Taiwan; <sup>20</sup>University of Washington Medical Center, Seattle, WA, USA; <sup>21</sup>Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany; <sup>22</sup>Department of Medical Oncology and University of British Columbia, BC Cancer, Vancouver, BC, Canada; <sup>23</sup>Calvary Mater Newcastle Hospital, Australia; <sup>24</sup>Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy; <sup>25</sup>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceuticals Limited; <sup>26</sup>Seagen Inc., Bothell, WA, USA; <sup>27</sup>Universitätsmedizin Göttingen, Göttingen, Germany

## Burkitt Lymphoma: Unexpected Cause of Abdominal Fullness in Pregnancy

Tien-Chan Hsieh, MD<sup>1,2,3</sup>, Russell Lewis, Jr, MD<sup>1</sup>, Sean X. Gu, MD/PhD<sup>4</sup>, Zenggang Pan, MD/PhD<sup>4</sup>, Stephanie Halene, MD/PhD<sup>1</sup>, <sup>1</sup>Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510; <sup>2</sup>Department of Medicine, Danbury Hospital, Danbury, CT, USA; <sup>3</sup>Department of Medicine, University of Vermont, Burlington, VT, USA; <sup>4</sup>Department of Pathology, Yale University School of Medicine, 310 Cedar Street New Haven, Connecticut, 06510

## Frontline Brentuximab Vedotin and CHP (A+CHP) In Patients with Peripheral T-Cell Lymphoma with <10% CD30 Expression (SGN35032, Trial In Progress)

Deepa Jagadeesh<sup>1</sup>, Scott Knowles<sup>2</sup>, Steven M. Horwitz<sup>3</sup>, <sup>1</sup>Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH, USA; <sup>2</sup>Seagen Inc. and University of Washington, Bothell and Seattle, WA, USA; <sup>3</sup>Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

## Clinical Activity of Loncastuximab Tesirine Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results

M Janakiram<sup>1</sup>, J Depaus<sup>2</sup>, N Wagner-Johnston<sup>3</sup>, P L Zinzani<sup>4</sup>, T J Phillips<sup>5</sup>, S Ferrari<sup>6</sup>, L J Bryan<sup>7</sup>, V Delwail<sup>8</sup>, S de Guibert<sup>9</sup>, M Tani<sup>10</sup>, V Dai<sup>11</sup>, K Havenith<sup>12</sup>, J Boni<sup>11</sup>, X He<sup>11</sup>, A Ervin-Haynes<sup>11</sup>, C Carlo-Stella<sup>13</sup>, <sup>1</sup>Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; <sup>2</sup>Department of Hematology, CHU UCL Namur site Godinne, Yvoir, Belgium; <sup>3</sup>Division of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; <sup>4</sup>IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy; <sup>5</sup>University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; <sup>6</sup>Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; <sup>7</sup>Department of Medicine, Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA; <sup>8</sup>Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Poitiers, Poitiers, France; <sup>9</sup>Department of Clinical Hematology, Centre Hospitalier Universitaire de Rennes Hôpital Pontchaillou, Rennes, France; <sup>10</sup>Unit of Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy; <sup>11</sup>Clinical Development, ADC Therapeutics America, Inc., Murray Hill, NJ, USA; <sup>12</sup>ADC Therapeutics (UK) Ltd, London, UK; <sup>13</sup>Department of Biomedical Sciences, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

## Racial, Ethnic, and Socioeconomic Disparities in Treatment Outcomes in Patients (PTS) with Diffuse Large B-Cell Lymphoma (DLBCL): A US Real-World Study Using a De-Identified Electronic Health Record (EHR)-Derived Database

Yanling Jin,<sup>1</sup> Jia Li,<sup>2</sup> Yong Mun,<sup>2</sup> Anthony Masaquel,<sup>2</sup> Sylvia Hu,<sup>2</sup> Juliana M. L. Biondo,<sup>2</sup> Scott Huntington<sup>3</sup>, <sup>1</sup>F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada; <sup>2</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>3</sup>Division of Hematology and Oncology, Department of Internal Medicine, Yale University, New Haven, CT, USA

## Congratulations to our 2021 PPLC Abstract Travel Stipend Recipients

Brendan Coutu, MD

Kaia Erickson, MD

Maria Guerrero, DNP, APRN, AOCNP

Tien-Chan Hsieh, MD

Aleksei Konstantinovich Koviazin, MD

Haleigh Mistry, PA

Vladimir Otasevic, MD

Justin Taylor, MD

### **LOTIS 2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma**

Brad S. Kahl<sup>1</sup>, Mehdi Hamadani<sup>2</sup>, Paolo F. Caimi<sup>3</sup>, Carmelo Carlo-Stella<sup>4</sup>, Weiyun Ai<sup>5</sup>, Juan Pablo Alderuccio<sup>6</sup>, Kirit M. Ardeshtna<sup>7</sup>, Brian Hess<sup>8</sup>, John Radford<sup>9</sup>, Melhem Solh<sup>10</sup>, Anastasios Stathis<sup>11</sup>, Jay Feingold<sup>12</sup>, David Ungar<sup>12</sup>, Yajuan Qin<sup>12</sup>, Shui He<sup>12</sup>, Pier Luigi Zinzani<sup>13</sup>, <sup>1</sup>Department of Medicine, Oncology Division, Washington University, St. Louis, MO, USA, <sup>2</sup>Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA, <sup>3</sup>University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, USA, <sup>4</sup>Department of Oncology and Hematology, Humanitas Clinical and Research Center – IRCCS, and Humanitas University, Rozzano, Milan, Italy, <sup>5</sup>Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA, <sup>6</sup>Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA, <sup>7</sup>Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK, <sup>8</sup>Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA, <sup>9</sup>NIHR Clinical Research Facility, Christie NHS Foundation Trust and the University of Manchester, Manchester, UK, <sup>10</sup>Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA, <sup>11</sup>Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, <sup>12</sup>Clinical Development, ADC Therapeutics America, Inc., Murray Hill, NJ, USA, <sup>13</sup>IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy

### **Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (PTS)**

Carmelo Carlo-Stella,<sup>1</sup> Cyrus Khan,<sup>2</sup> Martin Hutchings,<sup>3</sup> Fritz C. Offner,<sup>4</sup> Franck Morschhauser,<sup>5</sup> Emmanuel Bachy,<sup>6</sup> Michael Crump,<sup>7</sup> Anna Sureda,<sup>8</sup> Gloria Iacobi,<sup>9</sup> Corinne Haioun,<sup>10</sup> David Perez-Callejo,<sup>11</sup> Linda Lundberg,<sup>11</sup> James Relf,<sup>12</sup> Emma Clark,<sup>12</sup> David Carlile,<sup>12</sup> Emily Piccione,<sup>13</sup> Anton Belousov,<sup>11</sup> Kathryn Humphrey,<sup>12</sup> Michael J. Dickinson<sup>14</sup>, <sup>1</sup>Humanitas University and Humanitas Research Hospital, Milan, Italy; <sup>2</sup>Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA; <sup>3</sup>Rigshospitalet, Copenhagen, Denmark; <sup>4</sup>Universitair Ziekenhuis Gent, Ghent, Belgium; <sup>5</sup>Hôpital Claude Huriez and Centre Hospitalier Régional Universitaire de Lille, Lille, France; <sup>6</sup>Hospices Civils de Lyon and Université Claude Bernard, Pierre-Bénite, France; <sup>7</sup>Princess Margaret Hospital, Toronto, ON, Canada; <sup>8</sup>Institut Català d'Oncologia Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; <sup>9</sup>Vall d'Hebron University Hospital, Barcelona, Spain; <sup>10</sup>Hopital Henri Mondor, AP-HP, Créteil, France; <sup>11</sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland; <sup>12</sup>Roche Products Ltd, Welwyn Garden City, United Kingdom; <sup>13</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>14</sup>Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC, Australia

### **Upfront High-Dose Chemotherapy with Autologous Stem Cell Transplantation as a Prognostic Factor for IV Stage and High-Intermediate/High IPI Risk Groups of Diffuse Large B-Cell Lymphoma**

A.K. Koviazin<sup>1</sup>, L.V. Filatova<sup>1</sup>, I.S. Zyuzgin<sup>1</sup>, A.S. Artemyeva<sup>2</sup>, M.S. Motalkina<sup>1</sup>, Yu. A. Chudinovskikh<sup>1</sup>, S.A. Volchenkov<sup>1</sup>, I.L. Poliatskin<sup>2</sup>, E.V. Cherkasova<sup>1</sup>, S.A. Shalaev<sup>1</sup>, I.V. Ishmatova<sup>1</sup>, A.A. Zverkova<sup>1</sup>, M.I. Ghanzin<sup>1</sup>, D.S. Burda<sup>2</sup>, T.Yu. Semiglazova<sup>3</sup>, <sup>1</sup>Department of Hematology and Chemotherapy with intensive care unit, <sup>2</sup>Department of Pathology, <sup>3</sup>Department of Innovative Methods in Therapeutic Oncology and Rehabilitation, NMRC of Oncology named after N.N.Petrov of MoH of Russia, Saint-Petersburg, Russian Federation

# E-POSTERS

## **A Case Report of Rare Primary Colonic Diffuse Large B-Cell Lymphoma**

G. Libonate OMS-III<sup>1</sup>, K. Sankoorikal OMS-III<sup>1</sup>, K. McKay OMS-III<sup>1</sup>, S. Alrefai MD<sup>1,2</sup>, <sup>1</sup>Edward Via College of Osteopathic Medicine – Blacksburg, VA, United States of America; <sup>2</sup>Sentara Halifax Regional Hospital, Department of Surgery – South Boston, VA, USA

## **Encore — Economic Assessment of Diagnostic Revision in Peripheral T-Cell Lymphoma**

Nicholas Liu<sup>1</sup>, Julie Lisano<sup>1</sup>, Kristina S. Yu<sup>1</sup>, Deepak Singh<sup>1</sup>, David Campbell<sup>2</sup>, Wayne Su<sup>2</sup>, <sup>1</sup>Seagen, Bothell, WA, USA; <sup>2</sup>Xcenda, Palm Harbor, FL, USA

## **Treatment Patterns and Real-World Outcomes in Patients with Large B-Cell Lymphoma Who Received Second-Line Salvage Therapy**

Matthew Lunning<sup>1</sup>, Min Che<sup>2</sup>, Tao Gu<sup>2</sup>, T. Kim Le<sup>2</sup>, Fei Fei Liu<sup>2</sup>, <sup>1</sup>University of Nebraska Medical Center, Omaha, NE, USA; <sup>2</sup>Bristol Myers Squibb, Princeton, NJ, USA

## **Overview for the Advanced Practice Provider of 3rd Line Therapies for Large B-Cell Lymphoma in the Modern Era**

Mistry, H.E and Guerrero, M.D.; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

## **Multi Targeted Epigenetic Therapies in Lymphoma, A 10 Year Case Study of Successful Treatment of Advanced Mantle Cell Lymphoma**

M.Nezami MD, S.Hager DO, acknowledgement: P. Herschberger PhD., California Cancer Associates for Research and Excellence (Fresno, CA), Roswell Park Comprehensive Cancer Center (Buffalo, NY)

## **Impact of Prior Lines of Therapy on Outcomes Following Non-Transplant Therapy for Relapsed and Refractory DLBCL**

Grzegorz S. Nowakowski, Sanjal H. Desai, Carrie A. Thompson, Brian F. Kabat, Rebecca L. King, Yucai Wang, Luis F. Porrata, Umar Farooq, Thomas E. Witzig, James R. Cerhan, Brian K. Link, Steven M. Ansell, Thomas M. Haberman, Matthew J. Maurer, Mayo Clinic, Rochester, MN, USA and University of Iowa, Iowa City, IA, USA

## **Mosunetuzumab (MOSUN) Monotherapy for Elderly/Unfit Patients (PTS) with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses**

Adam Olszewski<sup>1</sup>, Abraham Avigdor<sup>2,3</sup>, Sunil Babu<sup>4</sup>, Itai Levi<sup>5</sup>, Herbert Eradat<sup>6</sup>, Uri Abadi<sup>3,7</sup>, Houston Holmes<sup>8</sup>, Matthew McKinney<sup>9</sup>, Dariusz Woszczyk<sup>10</sup>, Krzysztof Giannopoulos<sup>11</sup>, Wojciech Jurczak<sup>12</sup>, Ron McCord<sup>13</sup>, Yuying Xie<sup>14</sup>, Kati Sarouei<sup>13</sup>, Naseer Qayum<sup>15</sup>, Carol O'Hear<sup>13</sup>, Gila Sellam<sup>16</sup>, Netanel Horowitz<sup>17</sup>, <sup>1</sup>Brown University, Providence, RI, USA; <sup>2</sup>Sheba Medical Center, Ramat Gan, Israel; <sup>3</sup>Tel Aviv University, Tel Aviv, Israel; <sup>4</sup>Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN, USA; <sup>5</sup>Soroka University Medical Centre, Be'er-Sheva, Israel; <sup>6</sup>University of California, Los Angeles, CA, USA; <sup>7</sup>Meir Medical Center, Kfar Saba, Israel; <sup>8</sup>Texas Oncology, Dallas, TX, USA; <sup>9</sup>Duke Cancer Institute, Durham,

NC, USA; <sup>10</sup>University of Opole, Provincial Hospital, Opole, Poland; <sup>11</sup>Medical University of Lublin, Lublin, Poland; <sup>12</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland; <sup>13</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>14</sup>F. Hoffmann-La Roche Ltd, Mississauga, Canada; <sup>15</sup>Roche Products Ltd, Welwyn Garden City, United Kingdom; <sup>16</sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland; <sup>17</sup>Ramban Healthcare Campus, Hifa, Israel

## **THROLY Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication**

Vladimir Otasevic<sup>1</sup>, Darko Antic<sup>1,2</sup>, Sven Borchmann<sup>3</sup>, Horst Müller<sup>3</sup>, Andreas Engert<sup>3</sup>, Vojin Vukovic<sup>1</sup>, Kristina Tomic<sup>1</sup>, Biljana Mihaljevic<sup>1,2</sup>, Jawed Fareed<sup>4</sup>, <sup>1</sup>Lymphoma Center, Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia; <sup>2</sup>Faculty of Medicine, University of Belgrade, Serbia, <sup>3</sup>Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German Hodgkin Study Group (GHSg), University of Cologne, Cologne, Germany; <sup>4</sup>Loyola University Medical Center, Maywood, IL, USA

## **A Population-Based Simulation Model to Estimate Long-Term Progression-Free Survival and Stem Cell Transplantation for Stage III/IV Classical Hodgkin Lymphoma Based on 5-Year Update of the ECHELON-1 Trial: A US Perspective**

Tyrel Phillips<sup>1</sup>, Kristen Migliaccio-Walle<sup>2</sup>, Kristina S. Yu<sup>3</sup>, Brian Bloudek<sup>2</sup>, Nicholas Liu<sup>3</sup>, Michelle Fanale<sup>3</sup>, John M. Burke<sup>4</sup>, <sup>1</sup>Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; <sup>2</sup>Curta Inc., Seattle, WA, USA; <sup>3</sup>Seagen Inc., Bothell, WA, USA; <sup>4</sup>US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA

## **Outcomes for Recurrent Mantle Cell Lymphoma Post-BTK Inhibitor Therapy in Japan; An Administrative Database Study**

Shinya Rai<sup>1</sup>, Yoshinori Tanizawa<sup>2</sup>, Zhihong Cai<sup>2</sup>, Masaomi Tajimi<sup>2</sup>, Hiroya Asou<sup>2</sup>, Yu-Jing Huang<sup>3</sup>, Kaisa Taipale<sup>4</sup>, Lee Bowman<sup>3</sup>, <sup>1</sup>Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-sayama, Japan; <sup>2</sup>Eli Lilly Japan K.K., Kobe, Japan; <sup>3</sup>Eli Lilly and Company, Indianapolis, USA; <sup>4</sup>Oy Eli Lilly Finland AB, Helsinki, Finland

## **Transformation of Follicular Lymphoma Into Primary Mediastinal B Cell Lymphoma-Like Large B Cell Lymphoma**

Lisa Rimsza<sup>1</sup>, Sarah Gibson<sup>1</sup>, Colleen Ramsower<sup>1</sup>, Tameson Yip<sup>1</sup>, Allison Rosenthal<sup>2</sup>, Ryan Robetorye<sup>1</sup>, Karen Rech<sup>3</sup>, James R. Cook<sup>4</sup>, Gerben Duns<sup>5</sup>, Christian Steidl<sup>5</sup>, <sup>1</sup>Dept. of Laboratory Medicine and Pathology, Mayo Clinic, Arizona; <sup>2</sup>Dept. of Internal Medicine, Mayo Clinic Arizona; <sup>3</sup>Dept. of Laboratory Medicine and Pathology, Mayo Clinic Rochester; <sup>4</sup>Department of Clinical Pathology, Cleveland Clinic, Ohio; <sup>5</sup>Dept. of Lymphoid Malignancies, British Columbia Cancer Agency, Vancouver, CA

## **Distinguishing Between Primary Mediastinal Large B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma Using the LYMPH3CX Assay in a Clinical Molecular Diagnostics Laboratory**

Ryan S. Robetorye, MD, PhD, Colleen A. Ramsower, and Lisa M. Rimsza, MD, Molecular Diagnostics - Arizona Lab (MDAZL), Department of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Scottsdale, AZ, USA

## **A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with CHL, SALCL, or Other CD30 Expressing PTCL (SGN35-28, Trial In Progress)**

Jose D Sandoval-Sus<sup>1</sup>, Scott Knowles<sup>2</sup>, Julie Lisano<sup>2</sup>, Jingmin Liu<sup>2</sup>, Sairah Ahmed<sup>3</sup>, <sup>1</sup>Department of Malignant Hematology & Cellular Therapy, H Lee Moffitt Cancer Center at Memorial Cancer Institute, Pembroke Pines, FL, US; <sup>2</sup>Seagen Inc. Bothell, WA, US; <sup>3</sup>MD Anderson Cancer Center, Houston, TX, USA

## **Preliminary Results of the Phase 2 Study of Zanubrutinib in Patients with Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib**

Mazyar Shadman, MD, MPH<sup>1</sup>, Jeff P. Sharman, MD<sup>2</sup>, Moshe Y. Levy, MD<sup>3</sup>, Ryan Porter, MD<sup>4</sup>, Syed F. Zafar, MD<sup>5</sup>, John M. Burke, MD<sup>6</sup>, Arvind Chaudhry, MD, PhD<sup>7</sup>, Benjamin Freeman, MD<sup>8</sup>, Jamal Misleh, MD<sup>9</sup>, Habte A. Yimer, MD<sup>10</sup>, Jennifer L. Cultrera, MD<sup>11</sup>, Troy H. Guthrie, MD<sup>12</sup>, Edwin Kingsley, MD<sup>13</sup>, Subramanya S. Rao, MD<sup>14</sup>, Dih-Yih Chen, MD<sup>15</sup>, Xiaoping Zhang, MD<sup>15</sup>, Adam Idoine, PhD<sup>15</sup>, Aileen Cohen, MD, PhD<sup>15</sup>, Kunthel By, PhD<sup>15</sup>, Jane Huang, MD<sup>15</sup>, Ian Flinn, MD, PhD<sup>15</sup>, <sup>1</sup>Fred Hutchinson Cancer Research Center, University of Washington, Clinical Research Division, PO Box 19024, 1100 Fairview Ave N, Seattle, WA, 98109 USA; <sup>2</sup>Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA; <sup>3</sup>Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA; <sup>4</sup>SSM Health Dean Medical Group, Madison, WI, USA; <sup>5</sup>Florida Cancer Specialists & Research Institute, Fort Myers, FL, USA; <sup>6</sup>Rocky Mountain Cancer Centers, Aurora, CO, USA; <sup>7</sup>Summit Cancer Centers, Spokane, WA, USA; <sup>8</sup>Summit Medical Group, Florham Park, NJ, USA; <sup>9</sup>Medical Oncology Hematology Consultants PA, Newark, DE, USA; <sup>10</sup>Texas Oncology-Tyler, Tyler, TX, USA; <sup>11</sup>Florida Cancer Specialists & Research Institute, Leesburg, FL, USA; <sup>12</sup>GenesisCare, Jacksonville, FL, USA; <sup>13</sup>Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; <sup>14</sup>Alpha Med Physicians Group, Tinley Park, IL, USA; <sup>15</sup>BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA; <sup>16</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA

## **Updated Experience from Mosunetuzumab in Multiply Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial**

Sarit Assouline,<sup>1</sup> Won Seog Kim,<sup>2</sup> Laurie H. Sehn,<sup>3</sup> Stephen J. Schuster,<sup>4</sup> Chan Yoon Cheah,<sup>5</sup> Loretta J. Nastoupil,<sup>6</sup> Mazyar Shadman,<sup>7</sup> Sung-Soo Yoon,<sup>8</sup> Matthew J. Matasar,<sup>9</sup> Catherine Diefenbach,<sup>10</sup> Gareth P. Gregory,<sup>11</sup> Nancy L. Bartlett,<sup>12</sup> Michael C. Wei,<sup>13</sup> Michelle Y. Doral,<sup>13</sup> Shen Yin,<sup>13</sup> Raluca Negricea,<sup>14</sup> Chi-Chung Li,<sup>13</sup> Elicia Penuel,<sup>13</sup> Huang Huang,<sup>14</sup> L. Elizabeth Budde<sup>15</sup>, <sup>1</sup>Jewish General Hospital, Montreal, QC, Canada; <sup>2</sup>Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea; <sup>3</sup>BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada; <sup>4</sup>Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; <sup>5</sup>Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, WA, Australia; <sup>6</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>7</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA; <sup>8</sup>Seoul National University Hospital, Seoul, Republic of Korea; <sup>9</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>10</sup>Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA; <sup>11</sup>School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; <sup>12</sup>Washington University School of Medicine, St. Louis, MO, USA; <sup>13</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>14</sup>F. Hoffmann-La Roche Limited, Mississauga, ON, Canada; <sup>15</sup>City of Hope National Medical Center, Duarte, CA, USA

## **Composite Biomarker Image: Advanced Visualisation for Examination of Hodgkin Lymphoma**

Abubakr Shafique<sup>1</sup>, Morteza Babaie<sup>1</sup>, Adrian Batten<sup>2</sup>, Soma Skdar<sup>2</sup>, and Hamid Tizhoosh<sup>1</sup>, <sup>1</sup>Kimia Lab, University of Waterloo, Waterloo, ON, Canada, <sup>2</sup>Grand River Hospital, Kitchener, ON, Canada

## **Cost-Effective of Radiotherapy in the PET/CT-ERA for Early-Stage Hodgkin's Lymphoma**

Hayeon Kim PhD<sup>1</sup>, Adam Richman MD<sup>1</sup>, Kenneth J Smith MD MS<sup>2</sup>, Parvez M Shaikh MD<sup>3</sup>, Sushil Beriwal MD MBA<sup>1</sup>, John A. Vargo MD<sup>1</sup>, <sup>1</sup>Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA <sup>2</sup>Clinical and Translational Science and Center for Research on Health Care, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA <sup>3</sup>Department of Radiation Oncology, West Virginia University, Morgantown, WV, USA

## **Healthcare Utilization and Costs Associated with First-Line Treatment with Obinutuzumab- and Rituximab-Based Regimens for Follicular Lymphoma**

Jamie T. Ta,<sup>1</sup> Tu My To,<sup>1</sup> Cheryl Sud,<sup>1</sup> Sheila Shapouri,<sup>1</sup> Arpamas Seetasith<sup>1</sup>, <sup>1</sup>Genentech, Inc., South San Francisco, CA, USA

## **Phase 2 Trial of Entospletinib (GS-9973), a Selective syk Inhibitor, in Diffuse Large B-Cell Lymphoma (DLBCL)**

Jeff Porter Sharman, Andrei Shustov, James Essell, Dipti Patel-Donnelly, Thomas Rado, Jay Yang, Siddhartha Mitra, Esteban Abella, Jing He, Jing Hu, Robert Chen, Sarit Assouline, John Burke, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Springfield, OR; University of Washington Medical Center, Seattle WA; City of Hope, Duarte, CA; Oncology Hematology Care, Cincinnati, OH; Virginia Cancer Specialists/US Oncology Research, Fairfax, VA; Kadlec Clinic, Richland, WA; Karmanos Cancer Institute/Wayne State University, Detroit, MI; Gilead Sciences, Inc, Foster City, CA; Gerald Bronfman Centre/McGill University, Montreal, Canada; Rocky Mountain Cancer Centers/US Oncology Research, Aurora, CO

## **Umbralisib Improves Tolerability and Associated Cost Burden of Adverse Events Over PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma Patients: Results from Matching-Adjusted Indirect Comparison**

Sushanth Jeyakumar<sup>1</sup>, Sanatan Shrey<sup>2</sup>, Jaime Barnes<sup>2</sup>, Nathaniel Smith<sup>1</sup>, Yanzhi Hsu<sup>2</sup> and Hari Miskin<sup>2</sup>, <sup>1</sup>Maple Health Group, LLC, New York, NY, USA, <sup>2</sup>TG Therapeutics, New York, NY, USA

## **ALLO-HSCT after Mogamulizumab Treatment in MF or SS**

Mary Jo Lechowicz, MD<sup>1</sup>; Christy Smith, DNP, ACNP-BC<sup>2</sup>; Robert Ristuccia, PhD<sup>2</sup>; Karen Dwyer, BA<sup>3</sup>, <sup>1</sup>The Winship Cancer Institute Emory University, Atlanta, GA, USA; <sup>2</sup>Kyowa Kirin, Inc., Bedminster, NJ, USA; <sup>3</sup>Kyowa Kirin, Inc., Princeton, NJ, USA

# E-POSTERS

## **Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study**

David J. Straus,<sup>1</sup> Monika Długosz-Danecka,<sup>2</sup> Joseph M. Connors,<sup>3</sup> Árpád Illés,<sup>4</sup> Marco Picardi,<sup>5</sup> Ewa Lech-Maranda,<sup>6</sup> Tatyana Feldman,<sup>7</sup> Piotr Smolewski,<sup>8</sup> Kerry J. Savage,<sup>3</sup> Nancy L. Bartlett,<sup>9</sup> Jan Walewski,<sup>10</sup> Radhakrishnan Ramchandren,<sup>11</sup> Pier Luigi Zinzani,<sup>12</sup> Martin Hutchings,<sup>13</sup> Javier Munoz,<sup>14</sup> Won Seog Kim,<sup>15</sup> Ranjana Advani,<sup>16</sup> Stephen M. Ansell,<sup>17</sup> Anas Younes,<sup>18</sup> Andrea Gallamini,<sup>19</sup> Sergey Alekseev,<sup>20</sup> Hun Ju Lee,<sup>21</sup> Rachael Liu,<sup>22</sup> Meredith Little,<sup>22</sup> Keenan Fenton,<sup>23</sup> Michelle Fanale,<sup>23</sup> John Radford<sup>24</sup>, <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA; <sup>2</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland; <sup>3</sup>BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada; <sup>4</sup>University of Debrecen, Debrecen, Hungary; <sup>5</sup>Federico II University, Naples, Italy; <sup>6</sup>Institute of Hematology and Transfusion Medicine, Warsaw, Poland; <sup>7</sup>Hackensack University Medical Center, Hackensack, NJ, USA; <sup>8</sup>Medical University of Lodz, Poland; <sup>9</sup>Siteman Cancer Center, St. Louis, MO, USA; <sup>10</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; <sup>11</sup>The University of Tennessee Graduate School of Medicine, Knoxville, TN, USA; <sup>12</sup>Seragnoli Institute of Hematology, Bologna University, Bologna, Italy; <sup>13</sup>Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; <sup>14</sup>Banner MD Anderson Cancer Center, Gilbert, AZ, USA; <sup>15</sup>Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; <sup>16</sup>Stanford University, Stanford, CA, USA; <sup>17</sup>Mayo Clinic, Rochester, MN, USA; <sup>18</sup>AstraZeneca US, Wilmington, DE, USA; <sup>19</sup>Antoine-Lacassagne Cancer Centre, Nice, France; <sup>20</sup>Petrov Research Institute of Oncology, St Petersburg, Russia; <sup>21</sup>University of Texas MD Anderson Cancer Center, Houston, TX, USA; <sup>22</sup>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; <sup>23</sup>Seagen Inc., Bothell, WA, USA; <sup>24</sup>University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

## **Real-World Treatment Patterns and Outcomes in Patients with Follicular Lymphoma in the United States**

Jamie T. Ta,<sup>1</sup> Taha Itani,<sup>2</sup> Sheila Shapouri,<sup>1</sup> Stella Arndorfer,<sup>3</sup> Cristina Julian,<sup>1</sup> Mei Wu,<sup>1</sup> Giovanni d'Ario,<sup>4</sup> Cheryl Sud<sup>1</sup>, <sup>1</sup>Genentech, Inc., South San Francisco, CA, USA; <sup>2</sup>Roche Products Ltd, Welwyn Garden City, England; <sup>3</sup>Genesis Research, Hoboken, NJ, USA; <sup>4</sup>F. Hoffmann-La Roche Ltd, Basel, Switzerland

## **Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study**

Justin Taylor<sup>1</sup>, John M. Pagel<sup>2</sup>, Catherine C. Coombs<sup>3</sup>, Nirav N. Shah<sup>4</sup>, Nicole Lamanna<sup>5</sup>, Ewa Lech-Maranda<sup>6</sup>, Toby A. Eyre<sup>7</sup>, Jennifer A. Woyach<sup>8</sup>, William G. Wierda<sup>9</sup>, Chan Y. Cheah<sup>10</sup>, Lindsey E. Roeker<sup>11</sup>, Manish R. Patel<sup>12</sup>, Bitu Fakhri<sup>13</sup>, Minal A. Barve<sup>14</sup>, Constantine S. Tam<sup>15</sup>, David J. Lewis<sup>16</sup>, James N. Gerson<sup>17</sup>, Alvaro Alencar<sup>1</sup>, Omar Abdel-Wahab<sup>11</sup>, Paolo Ghia<sup>18</sup>, Stephen J. Schuster<sup>17</sup>, Jessica Chen<sup>19</sup>, Binoj Nair<sup>20</sup>, Donald E. Tsai<sup>20</sup>, Nora C. Ku<sup>20</sup>, Matthew S. Davids<sup>21</sup>, Jennifer R. Brown<sup>21</sup>, Wojciech Jurczak<sup>22</sup>, Anthony R. Mato<sup>11</sup>, <sup>1</sup>University of Miami Miller School of Medicine, Miami, USA; <sup>2</sup>Swedish Cancer Institute, Seattle, USA; <sup>3</sup>University of North Carolina at Chapel Hill, Chapel Hill, USA; <sup>4</sup>Medical College of Wisconsin, Milwaukee, USA; <sup>5</sup>Herbert Irving Comprehensive Cancer Center,

Columbia University, New York, USA; <sup>6</sup>Institute of Hematology and Transfusion Medicine, Warsaw, Poland; <sup>7</sup>Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK; <sup>8</sup>The Ohio State University Comprehensive Cancer Center, Columbus, USA; <sup>9</sup>MD Anderson Cancer Center, Houston, USA; <sup>10</sup>Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; <sup>11</sup>Memorial Sloan Kettering Cancer Center, New York, USA; <sup>12</sup>Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, USA; <sup>13</sup>University of California San Francisco, San Francisco, USA; <sup>14</sup>Mary Crowley Cancer Research, Dallas, USA; <sup>15</sup>Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; <sup>16</sup>Plymouth Hospitals NHS Trust – Derriford Hospital, Plymouth, UK; <sup>17</sup>Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA; <sup>18</sup>Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; <sup>19</sup>Eli Lilly and Company, Indianapolis, IN, USA; <sup>20</sup>Loxo Oncology, Inc, a wholly owned subsidiary of Eli Lilly and Co., Stamford, CT, USA; <sup>21</sup>Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA; <sup>22</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

## **Progression-Free Survival at 24 Months as a Landmark after Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-Cell Lymphoma**

Aung M. Tun,<sup>1</sup> Seth Maliske,<sup>2</sup> Yucai Wang,<sup>3</sup> Matthew J. Maurer,<sup>4</sup> Ivana N. M. Micallef,<sup>3</sup> David James Inwards,<sup>3</sup> Luis F. Porrata,<sup>3</sup> Allison Claire Rosenthal,<sup>5</sup> Mohamed Kharfan-Dabaja,<sup>6</sup> Jacob Orme,<sup>3</sup> Brian K. Link,<sup>7</sup> James Robert Cerhan,<sup>4</sup> Carrie A. Thompson,<sup>3</sup> Thomas Matthew Habermann,<sup>3</sup> Thomas E. Witzig,<sup>3</sup> Stephen M. Ansell,<sup>3</sup> Grzegorz S. Nowakowski,<sup>3</sup> Umar Farooq,<sup>2</sup> Patrick B. Johnston<sup>3</sup>, <sup>1</sup>The University of Kansas Cancer Center, Westwood, KS, USA; <sup>2</sup>University of Iowa, Iowa City, IA, USA; <sup>3</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA; <sup>4</sup>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; <sup>5</sup>Division of Hematology, Mayo Clinic, Phoenix, AZ, USA; <sup>6</sup>Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA; <sup>7</sup>University of Iowa Carver College of Medicine, Iowa City, IA, USA

## **FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-Chop vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma**

Umberto Vitolo,<sup>1</sup> Grzegorz S. Nowakowski,<sup>2</sup> John M. Burke,<sup>3</sup> Christopher P. Fox,<sup>4</sup> Marek Trnety,<sup>5</sup> Annalisa Chiappella,<sup>6</sup> Sascha Tillmanns,<sup>7</sup> Andrea Sporchia,<sup>7</sup> Wolfram Brugger,<sup>7</sup> Georg Lenz<sup>8</sup>, <sup>1</sup>Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy; <sup>2</sup>Division of Hematology, Mayo Clinic, Rochester, MN, USA; <sup>3</sup>US Oncology Research and Rocky Mountain Cancer Centers, Aurora, CO, USA; <sup>4</sup>Department of Clinical Haematology, Nottingham University Hospitals NHS, Nottingham, UK; <sup>5</sup>1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic; <sup>6</sup>Division of Hematology & Stem Cell Transplant, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy; <sup>7</sup>MorphoSys AG, Planegg, Germany; <sup>8</sup>Department of Medicine A – Haematology and Oncology, University Hospital Münster, Münster, Germany

### **Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from a Phase 2 Study**

Wang M,<sup>1</sup> Rule S,<sup>2</sup> Zinzani PL,<sup>3</sup> Goy A,<sup>4</sup> Casasnovas O,<sup>5</sup> Smith SD,<sup>6</sup> Damaj G,<sup>7</sup> Doorduijn JK,<sup>8</sup> Lamy T,<sup>9</sup> Morschhauser F,<sup>10</sup> Panizo C,<sup>11</sup> Shah B,<sup>12</sup> Davies A,<sup>13</sup> Eek R,<sup>14</sup> Dupuis J,<sup>15</sup> Jacobsen E,<sup>16</sup> Kater AP,<sup>17</sup> Le Gouill S,<sup>18</sup> Oberic L,<sup>19</sup> Robak T,<sup>20</sup> Jain P,<sup>1</sup> Calvo R,<sup>21</sup> Tao L,<sup>22</sup> Długosz-Danecka M,<sup>23</sup> <sup>1</sup>MD Anderson Cancer Center, University of Texas, Houston, TX, USA; <sup>2</sup>Plymouth University Medical School, Plymouth, UK; <sup>3</sup>Institute of Hematology "Seràgnoli," University of Bologna, Bologna, Italy; <sup>4</sup>John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; <sup>5</sup>CHU Dijon - Hôpital d'Enfants, Dijon, France; <sup>6</sup>Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA; <sup>7</sup>Institut d'Hématologie de Basse-Normandie, Caen, France; <sup>8</sup>Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands; <sup>9</sup>CHU de Rennes, Rennes, France; <sup>10</sup>CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées Lille, France; <sup>11</sup>Clinica Universidad de Navarra, Pamplona, Spain; <sup>12</sup>Moffitt Cancer Center, Tampa, FL, USA; <sup>13</sup>Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton Faculty of Medicine, Southampton, UK; <sup>14</sup>Border Medical Oncology, Albury, Victoria, Australia; <sup>15</sup>Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France; <sup>16</sup>Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; <sup>17</sup>Amsterdam University Medical Center, Amsterdam, on behalf of Hovon, Netherlands; <sup>18</sup>CHU de Nantes—Hotel Dieu, Nantes, France; <sup>19</sup>Institut Universitaire du Cancer—Oncopole Toulouse (IUCT-O), Toulouse, France; <sup>20</sup>Medical University of Lodz, Lodz, Poland; <sup>21</sup>AstraZeneca, Gaithersburg, MD, USA; <sup>22</sup>AstraZeneca, South San Francisco, CA, USA; <sup>23</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

### **In-Class Transition from Parenteral to Oral Proteasome Inhibitor (PI)-Based Therapy: Overview of Current Ixazomib Trials in Multiple Myeloma (MM)**

Presley Whidden,<sup>1</sup> Hans C. Lee,<sup>2</sup> Stephen J. Noga,<sup>1</sup> Ajay K. Nooka,<sup>3</sup> Wenming Chen,<sup>4</sup> Kenshi Suzuki,<sup>5</sup> Renda H. Ferrari,<sup>1</sup> Ruth Williams,<sup>1</sup> Robert M. Rifkin,<sup>6</sup> <sup>1</sup>Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; <sup>2</sup>MD Anderson Cancer Center, Houston, TX, USA; <sup>3</sup>Emory University Hospital/Winship Cancer Institute, Atlanta, GA, USA; <sup>4</sup>Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; <sup>5</sup>Japan Red Cross Medical Center, Shibuya-ku, Tokyo, Japan; <sup>6</sup>Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO, USA

### **Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher Risk (HR) Myelodysplastic Syndrome (MDS): The Phase 3, Randomized, Enhance Study**

Guillermo Garcia-Manero, MD<sup>1</sup>, Naval G. Daver<sup>1</sup>, Jin Xu<sup>2</sup>, Mark Chao<sup>2</sup>, Trisha Chung<sup>2</sup>, Anderson Tan<sup>2</sup>, Vivian Wang<sup>2</sup>, Andrew H. Wei<sup>3</sup>, Paresh Vyas<sup>4</sup>, and David A. Sallman<sup>5</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston Texas, USA; <sup>2</sup>Gilead Sciences, Inc., Foster City, CA, USA; <sup>3</sup>The Alfred Hospital and Monash University, Melbourne, Australia; <sup>4</sup>University of Oxford, Oxford, United Kingdom; <sup>5</sup>Moffitt Cancer Center, Tampa, FL, USA

### **ENCORE — Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective**

Christopher Yasenchak<sup>1</sup>, Nicholas Liu<sup>2</sup>, April Beeks<sup>3</sup>, Michelle Fanale<sup>2</sup>, Nicholas Robert<sup>3</sup>, Kristina S. Yu<sup>2</sup>, <sup>1</sup>Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA; <sup>2</sup>Seagen Inc., Bothell, WA, USA; <sup>3</sup>McKesson Life Sciences, The Woodlands, TX, USA

### **A Population-Based Simulation Model to Estimate Long-Term Progression-Free Survival and Overall Survival Based on 5-Year Update from ECHOLON-2 Trial in Patients with Peripheral T-Cell Lymphoma: A US Perspective**

Kristina S. Yu<sup>1</sup>, Tycel Phillips<sup>2</sup>, Uche Mordi<sup>3</sup>, Brian Bloudek<sup>3</sup>, Nicholas Liu<sup>1</sup>, Michelle Fanale<sup>1</sup>, John M. Burke<sup>4</sup>, <sup>1</sup>Seagen Inc., Bothell, WA, USA; <sup>2</sup>Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; <sup>3</sup>Curta Inc., Seattle, WA, USA; <sup>4</sup>US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA

### **How Should We Approach Hodgkin Lymphoma (HL) Patients with an Extra Lymphatic Disease (Eld) in the Era of Novel Therapies?**

Meltem Kurt Yuksel, Gul Yavuz<sup>1</sup>, Cemalettin Ozturk<sup>1</sup>, Atilla Uslu<sup>1</sup>, Isinsu Kuzu<sup>2</sup>. <sup>1</sup>Ankara University School of Medicine Hematology Department and BMT Unit Ankara Turkey; <sup>2</sup>Ankara University School of Medicine Pathology Department Ankara Turkey

### **Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 PRIMO Trial: Updated Expansion Phase Results**

<sup>1</sup>Jasmine Zain, <sup>2</sup>Pier Luigi Zinzani, <sup>3</sup>Jonathan E Brammer, <sup>4</sup>Monica Mead, <sup>5</sup>Carla Casulo, <sup>6</sup>Eric Jacobsen, <sup>7</sup>Giuseppe Gritti, <sup>8</sup>Debra Litwak, <sup>8</sup>David Cohan, <sup>9</sup>Neha Mehta-Shah, <sup>10</sup>Barbara Pro, <sup>11</sup>Steven M. Horwitz, <sup>1</sup>City of Hope, Duarte, California; <sup>2</sup>Institute of Hematology University of Bologna, Bologna, Italy; <sup>3</sup>The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio; <sup>4</sup>University of California Los Angeles, California; <sup>5</sup>University of Rochester, Wilmot Cancer Institute, Rochester, New York; <sup>6</sup>Dana-Farber Cancer Institute, Boston, Massachusetts; <sup>7</sup>Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy; <sup>8</sup>Secura Bio, Las Vegas, NV; <sup>9</sup>Washington University School of Medicine in St. Louis, St Louis, Missouri; <sup>10</sup>Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois; <sup>11</sup>Memorial Sloan Kettering Cancer Center, New York, New York

# CONFERENCE SPONSORS

## *University of Nebraska Medical Center (Accreditor)*

As Nebraska's only public academic health sciences center, the University of Nebraska Medical Center (UNMC) is committed to the education of a 21st century health care work force, to finding cures and treatments for devastating diseases, to providing the best care for patients, and to serving our state and its communities through award-winning outreach. UNMC is also committed to embracing the richness of diversity and is a major economic engine for the state of Nebraska. Led by Chancellor Jeffrey P. Gold, MD, UNMC has six colleges, two institutes, and a graduate studies program, serving nearly 4,000 students in more than two dozen programs. As an academic health science center, UNMC offers patients world-class healthcare, backed by the latest research innovations and practiced by faculty training the next generation of health care providers. With our hospital partner, Nebraska Medicine, UNMC provides services in about 50 specialties, including cancer, neurosciences, heart disease and others. Through this unique combination of academic, scientific, and health care experience, UNMC transforms the discoveries of the laboratory and theory of the classroom into breakthroughs for health.

The mission of the UNMC Continuing Education Programs is to provide specialized and inter-professional educational activities and support innovative research that facilitate individual skills and team-based performance that improves outcomes for patients and communities. Accordingly, UNMC's continuing education efforts aim to enhance the knowledge, skills, attitudes, competence and performance of health care professionals, ultimately improving patient outcomes and community health. This mission statement drives and unifies the continuing education efforts of all colleges and departments at UNMC.

The UNMC Center for Continuing Education (UNMC CCE) is one of this country's oldest accredited providers of continuing education to physicians, started in 1958. By 1967, UNMC CCE, was one of the first seven medical school programs to be ACCME accredited. Throughout its history, UNMC CCE's level and number of activities have grown in certified activities offered, variety of topics, delivery modes, and diversity of audience participants. UNMC CCE offers a broad range of activities from primary care issues to the latest developments in medicine and draws attendees throughout the region, nationally and internationally.

The UNMC College of Nursing Continuing Nursing Education (UNMC CON CNE) has been serving the profession since 1967. Thorough the

creation of engaging continuing nursing education products using state-of-the-art technologies and innovative educational modalities, we strive to improve patient outcomes in Nebraska and around the globe. Our highly developed technical capabilities include instructional design and module development, video streaming, learning activity hosting, custom web development, visual design, dynamic web pages, and data collection, storage, and analysis. The UNMC CON CNE is approved by the California Board of Registered Nursing, and is able to take accredited programs into all 50 states and beyond.

In pursuit of our collective mission, UNMC CCE and UNMC CON CNE work collaboratively to sponsor multi-professional educational activities designed to improve the performance of the health care team and thus patient outcomes. To forward an integrated team-based approach and to facilitate multi-disciplinary and specialized training, UNMC achieved Joint Accreditation provider status effective through November 2024.

## *UNMC Department of Internal Medicine - Division of Oncology and Hematology*

Renowned for the diagnosis, therapy, and research of lymphoma, the UNMC Department of Internal Medicine, Division of Oncology and Hematology has treated patients from all over the world. Patients come for consultation, initial diagnosis, second opinions, standard chemotherapy, participation in clinical research trials, stem cell transplants, and chimeric antigen receptor (CAR) T-cell therapies.

The Division of Oncology and Hematology is comprised of 27 faculty and physicians, with six specializing in lymphoma. The Division is interested in the diagnosis and treatment of all malignancies (cancers). Treatment may include chemotherapy, radiation therapy, immunotherapy, pathway targeted agents, or cellular therapies, including CAR T-cell therapy and bone marrow transplantation.

The Division's physicians specialize in many types of cancers including lymphomas, leukemia, multiple myeloma, urologic, breast, lung, gastric and pancreatic, neuro-oncologic, brain cancer, melanoma, hepatocellular, and other solid tumors.

## *Nebraska Medicine*

Nebraska Medicine is the most esteemed academic health system in the region, consisting of 809 licensed beds at its two hospitals, more than 1,000 physicians, and 40 specialty and primary care clinics in Omaha and surrounding areas.

Nebraska Medicine and UNMC, its research and education partner, share the same mission: to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.

Nebraska Medicine traces its roots back to 1869 with the founding of Omaha's first hospital. In the decades since, it has built an international reputation for breakthroughs in cancer care, organ transplantation and treatment of infectious diseases.

In 2017, Nebraska Medicine earned the Bernard A. Birnbaum, MD Quality Leadership Award from Vizient, Inc. which recognizes it in the top ten quality academic health systems in the United States. For five straight years, Nebraska Medicine has also been named to Becker's Hospital Review's list of 100 Great Hospitals in America.

## *Fred & Pamela Buffett Cancer Center*

The UNMC Fred and Pamela Buffett Cancer Center is the region's only National Cancer Institute (NCI) designated cancer center and is a member of the National Comprehensive Cancer Network (NCCN). The NCCN is an alliance of the nation's 31 leading cancer centers that

develop and institute standards of care for the treatment of cancer and perform outcomes research with the goal of ensuring the delivery of high quality, cost-effective services to cancer patients nationwide.

The Fred & Pamela Buffett Cancer Center has begun changing forever the way cancer is diagnosed and treated. By harnessing the most advanced biomedical and technological tools available, we are increasingly identifying the drivers behind cancer and creating precise therapies that improve outcomes. Through the use of genomics and other new diagnostic tools, we are employing precision medicine to customize therapies and care for each cancer patient.

While all forms of cancer will be treated at the Fred & Pamela Buffett Cancer Center, because of their prevalence in society and the center's potential to have a significant impact in their treatment, the following focus areas have been selected: breast cancer and other women's cancers, head and neck cancers, leukemia and lymphoma, lung cancer, pancreatic and gastrointestinal cancers, and prostate cancer.

The Fred and Pamela Buffett Cancer Center, along with the C.L. Werner Cancer Hospital, aim to provide the side-by-side, rapid development of therapeutics and delivery to patients with cancer.



Photo courtesy of HDR © 2017 Dan Schwalm



University of Nebraska  
Medical Center  
Nebraska Medicine

SAVE THE DATE

2022 PAN PACIFIC  
**LYMPHOMA**  
CONFERENCE

July 18-22 • Grand Hyatt Kauai

CALL FOR ABSTRACTS

Deadline: Friday, April 22, 2022

FOR MORE INFORMATION [www.unmc.edu/panpacificlymphoma](http://www.unmc.edu/panpacificlymphoma)